HOME
>
臨床医学：一般
>
臨床医学一般
> 実践骨代謝マーカー

実践骨代謝マーカー

出版社：	メディカルレビュー社
発行日：	2003-04-10
分野：	臨床医学：一般 > 臨床医学一般
ISBN：	4896005651
電子書籍版：	2003-04-10 （第1版第1刷）

書籍・雑誌

≪全国送料無料でお届け≫

品切れ

4,400 円(税込)

電子書籍

章別単位で購入

ブラウザ、アプリ閲覧

2,200 円(税込)

購入する

商品紹介

本書は、骨粗鬆症を始め、骨代謝の異常を呈する疾患における骨代謝マーカーの実践しように役立つことを主眼とし、明日からの日常診療に広く利用されることが期待される

目次

実践骨代謝マーカー

―　目次　―

第1章　骨・コラーゲン代謝の基礎
1　骨代謝
2　Ｉ型コラーゲンの代謝

第2章　骨代謝マーカーの基礎的事項
1　骨代謝マーカーの測定方法
2　骨代謝マーカーの測定値に影響を与える要因
3　骨代謝マーカーの基準値
4　血中マーカーと尿中マーカー：長所と短所

第3章　骨代謝マーカーの各論：臨床応用
1　骨形成マーカー
2　骨吸収マーカー
3　その他のメーカー

第4章　骨粗鬆症と骨代謝マーカー
1　骨粗鬆症と骨代謝マーカー
2　骨代謝マーカーによる骨粗鬆症のスクリーニング
3　骨代謝マーカーによる骨量減少の予知
4　骨代謝マーカーによる骨折の予知
5　骨代謝マーカーによる治療効果のモニター

第5章　骨粗鬆症以外の疾患・状態と骨代謝マーカー
1　悪性腫瘍の骨転移
2　原発性副甲状腺機能亢進症
3　腎性骨異栄養症
4　骨Ｐａｇｅｔ病
5　甲状腺機能亢進症
6　関節リウマチと骨粗鬆症
7　小児科領域
8　微小重力

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第I章骨・コラーゲン代謝の基礎

P.36 掲載の参考文献

1) Owen, M.:Marrow stromal stem cells. J. Cell. Sci. 10(Suppl.):63-76, 1988

2) Caplan, A. I.:Mesellchymal stem cells. J. Orthop. Res. 9:641-650, 1991

3) Pittenger, M. F., Mackay, A. M., Beck, S. C. et al.:Multilineage potential of adult human mesenchymal stem cells. Science 284:143-147, 1999

4) Horwitz, E.M., Prockop, D.J., Fitzpatrick, L.A. et al.:Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat. Med. 5:309-319, 1999

5) Ferrari, G., Cusella-De Angelis, G., Coletta, M. et al:Muscle regeneration by bone marrow-derived myogenic progenitors. Science 279:1528-1530, 1998

6) Orlic, D., Kalstura, J., Chimenti, S. et al.:Bone marrow cells regenerate infarcted myocardium. Nature 410:701-705, 2001

7) Ikeda, T., Nomura, S., Yamaguchi, A. et al.:In situ hybridization of bone matrix proteins in undecalcified adult rat bone sections. J. Histochem. Cytochem. 40:1079-1088, 1992

8) Ducy, P., Desbois, C., Boyce, B. et al.:Increased bone formation in osteocalcin-deficient mice. Nature 382:448-452, 1996

9) Geoffroy, V., Ducy, P., Karsenty, G.:A PEBP2a/AML-1-related factor increases osteocalcin pro-moter activity through its binding to an osteoblast-specific cis-acting element. J. Biol Chem. 270:30973-30979, 1995

10) Ducy, P., Karsenty, G.:Two distinct osteoblast-specific cis-acting elements control expression of a mouse osteocalcin gene. Mol. Cell Biol. 15:1858-1869, 1995

11) Ducy, P., Zhang, R., Geoffroy, V. et al.:Cbfa 1/Osf2:a transcriptional activator of osteoblast differentiation. Cell 89:747-754, 1997

12) Komori, T., Yagi, H., Nomura, S. et al.:Target disruption of Cbfa 1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89:755-764, 1997

13) Liu, W., Toyosawa, S., Furuichi, T. et al.:Overexpression of Cbfa 1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures. J. Cell Biol. 155:157-166, 2001

14) Jochum, W.,David, J-P., Ellott, C. et al.:Increased bone formation and osteosclerosis in mice overexpressing the transcription factor Fra-1. Nat. Med. 6:980-984, 2000

15) Sabatakos, G., Sims, N. A., Chen, J. et al.:Overexpression of Delta Fos B transcription factor(s) increases bone formation and inhibits adipogenesis. Nat. Med. 6:985-990, 2000

16) Kodama, Y., Takeuchi, Y., Suzawa, M. et al.:Reduced expression of interleukin-11 in bone marrow stromal cells of senescence-accelerated mice(SAMP 6):relationship to osteopenia with enhanced adipogenesis. J. Bone Miner. Res. 9:1370-1377, 1998

17) Ishizuya, T., Yokose, S. Hori, M. et al.:Parathyroid hormone exerts disparate effects on osteoblast differentiation depending on exposure time in rat osteobllastic cells. J. Clin. Invest. 99:2961-2970, 1997

18) Rickard, D.J., Hofbauer, L. C., Bonde, S. K. et al.:Bone morphogenetic protein-6 production in human osteoblastic cell lines. Selective regulation by estrogen. J. Clin. Invest. 15:413-422, 1998

19) Katagiri, T., Yamaguchi, A., Komaki, M. et al.:Bone morphogenetic protein-2 converts the differentiation pathway of C2 C12 myoblasts into the osteoblast lineage. J. Cell Biol. 127:1755-1766, 1994

20) Chow, J., Tobias, J.H., Colston, K.W. et al.:Estrogen maintains trabecular bone volume in rats not only by suppression of bone resorption but also by stimulation of bone formation. J. Clin. Invest. 89:74-78, 1992

21) Ikeda, T., Yamaguchi, A., Yokose, S. et al.:Changes in biological activity of bone cells in ovariectomized rats revealed by in situ hybridization. J. Bone Miner. Res. 11:780-788, 1996

22) Yokose, S., Ishizuya, T., Ikeda, T. et al.:An estrogen deficiency caused by ovariectomy increases plasma levels of systemic factors that stimulate proliferation and differentiation of osteoblasts in rats. Endocrinology 137:469-478, 1996

23) Turner, R.T., Spelsberg, T.C.:Correlation between mRNA levels for bone cell proteins and bone formation in long bones of maturing rats. Am. J. Physiol. 261:E348-E353, 1991

24) Ikeda, T., Nagai, Y., Yamaguchi, A. et al.:Age-related reduction in bone matrix protein mRNA expression in rat bone tissues:application of histomorphometry to in situ hybridization. Bone 16:17-23, 1995

P.49 掲載の参考文献

1) Takahashi, N., Akatsu, T., Udagawa, N. et al.:Osteoblastic cells are involved in osteoclast formation. Endocrinology 123:2600-2602, 1988

2) Suda, T., Takahashi, N., Martin, T. J.:Modulation of osteoclast differentiation. Endocr. Rev. 13:66-80, 1992

3) Takeda, S., Yoshizawa, T., Nagai, Y. et al.:Stimulation of osteoclast formation by 1,25-dihydroxyvitamin D requires its binding to vitamin D receptor (VDR) in osteoblastic cells:studies using VDR knockout mice. Endocrinology 140:1005-1008, 1999

4) Liu, B. Y., Guo, J., Lanske, B. et al.:Conditionally immortalized murine bone marrow stromal cells mediate parathyroid hormone-dependent osteoclastogenesis in vitro. Endocrinology 139:1952-1964, 1998

5) Sakuma, Y., Tanaka, K., Suda, M. et al.:Crucial involvement of the EP 4 subtype of prostaglandin E receptor in osteoclast formation by proinflammatory cytokines and lipopolysaccharide. J. Bone Miner. Res. 15:218-227, 2000

6) Udagawa, N., Takahashi, N., Katagiri, T. et al.:Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J. Exp. Med. 182:1461-1468, 1995

7) Suda, T., Udagawa N., Takahashi N.:Osteoclast generation, in Principles of Bone Biology.(Raisz L. G., Rodan, G A., Bilezikian, J. P. eds.) Academic Press, San Diego, 1996, p.87-102

8) Jimi, E., Nakamura, I., Amano, H. et al.:Osteoclast function is activated by osteoblastic cells through a mechanism involving cell-to-cell. Endocrinology 137:2187-2190, 1996

9) Udagawa, N., Takahashi, N., Akatsu, T. et al.:Origin of osteoclasts:mature monocytes and macrophages are capable of differentiating into osteoclasts under a suitable microenvironment prepared by bone marrow-derived stromal cells. Proc. Natl. Acad. Sci. USA 87:7260-7264, 1990

10) Fujikawa, Y., Quinn, J. M., Sabokbar, A. et al.:The human osteoclast precursor circulates in the monocyte fraction. Endocrinology 137:4058-4060, 1996

11) Matsuzaki, K., Katayama, K., Takahashi, Y. et al.:Human osteoclast-like cells are formed from peripheral blood mononuclear cells in a co-culture with SaOS-2 cells transfected with the PTH/PTHrP receptor gene. Endocrinology 140:925-932, 1999

12) Takahashi, N., Udagawa, N., Tanaka, S. et al.:Postmitotic osteoclast precursors are mononuclear cells which express macrophage-associated phenotypes. Dev. Biol. 163:212-221, 1994

13) Hsu, H., Lacey, D. L., Dunstan, C. R. et al.:Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc. Natl. Acad. Sci. USA 96:3540-3545, 1999

14) Miyamoto, A., Kunisada, T., Hemmi, H. et al.:Establishment and characterization of an immortal macrophage-like cell line inducible to differentiate to osteoclasts. Biochem. Biophys. Res. Commun. 242:703-709, 1998

15) Takahashi, N., Udagawa, N, Akatsu, T. et al.:Role of colony stimulating factors in osteoclast development. J. Bone Miner. Res. 6:977-985, 1991

16) Yoshida, H., Hayashi, S., Kunisada, T. et al.:The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 345:442-444, 1990

17) Felix, R., Cecchini, M. G., and Fleisch, H.:Macrophage colony stimulating factor restores in vivo bone resorption in the op/op osteopetrotic mouse. Endocrinology 127:2592-2594, 1990.

18) Kodama, H., Yamasaki, A., Nose, M. et al.:Congenital osteoclast deficiency in osteopetrotic (op/op) mice is cured by injections of macrophage colony-stimulating factor. J. Exp. Med. 173:269-272, 1991

19) Tanaka, S., Takahashi, N., Udagawa, N. et al.:Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J. Clin. Invest. 91:257-263, 1993

20) Niida, S., Kaku, M., Amano, H. et al.:Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J. Exp. Med. 190:293-298, 1999

21) Itoh, K., Udagawa, N., Matsuzaki, K. et al.:Importance of membrane-or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors. J. Bone Miner. Res. 15:1766-1775, 2000

22) Simonet, W. S., Lacey, D. L., Dunstan, C. R. et al.:Osteoprotegerin:a novel secreted protein involved in the regulation of bone density. Cell 89:309-319, 1997

23) Tsuda, E., Goto, M., Mochizuki, S. et al.:Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem. Biophys. Res. Commun. 234:137-142, 1997

24) Yasuda, H., Shima, N., Nakagawa, N. et al.:Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc. Natl. Acad. Sci. USA 95:3597-3602, 1998

25) Lacey, D. L., Timms, E., Tan, H. et al.:Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176, 1998

26) Wong, B. R., Rho, J., Arron, J. et al.:TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells. J. Biol. Chem. 272:25190-25194, 1997

27) Anderson, D. M., Maraskovsky, E., Billingsley, W. L. et al.:A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390:175-179, 1997

28) The American Society for Bone and Mineral Research President's Committee on Nomenclature:Proposed standard nomenclature for new tumor necrosis factor family members involved in the regulation of bone resorption. J. Bone Miner. Res. 15:2293-2296, 2000

29) Takahashi, N., Udagawa, N., Suda T.:A new member of TNF ligand family, ODF/RANKL/TRANCE/OPGL, regulates osteoclast differentiation and function. Biochem. Biophys. Res. Commun. 256:449-455, 1999

30) Kong, Y. Y., Yoshida, H., Sarosi, I. et al:OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397:315-323, 1999

31) Dougall, W. C., Glaccum, M., Charrier, K. et al.:RANK is essential for osteoclast and lymph node development. Genes Dev. 13:2412-2424, 1999

32) Li, J., Sarosi, I., Yan, X. et al.:RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc. Natl. Acad. Sci. USA 97:1566-1571, 2000

33) Hughes, A. E., Ralston, S. H., Marken, J. et al.:Mutations in TNFRSF 11 A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat. Genet. 24:45-48, 2000

34) Jimi, E., Akiyama, S., Tsurukai, T. et al.:Osteoclast differentiation factor acts as a multifunctional regulator in murine osteoclast differentiation and function. J. Immunol. 163:434-442, 1999

35) Fuller, K., Wong, B., Fox, S. et al.:TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J. Exp. Med. 188:997-1001, 1998

36) Takami, M., Takahashi, N., Udagawa, N. et al.:Intracellular calcium and protein kinase C mediate expression of receptor activator of NF-κB ligand and osteoprotegerin in osteoblasts. Endocrinology 141:4711-4719, 2000

37) Kong, Y. Y., Feige, U., Sarosi, I. et al.:Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402:304-309, 1999

38) Ronaghy, A., Prakken, B.J., Takabayashi, K. et al.:Immunostimulatory DNA sequences influence the course of adjuvant arthritis. J. Immunol. 168:51-56, 2002

39) Darnay, B. G., Haridas, V., Ni, J. et al.:Characterization of the intracellular domain of receptor activator of NF-κB(RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-κB and c-Jun N-terminal kinase. J. Biol. Chem. 273:20551-20555, 1998

40) Darnay, B. G., Ni, J., Moore, P. A. et al.:Activation of NF-κB by RANK requires tumor necrosis factor receptor-associated factor(TRAF)6 and NF-κB-inducing kinase. Identification of a novel TRAF 6 interaction motif. J. Biol. Chem. 274:7724-7731, 1999

40) Kim, H. H., Lee, D. E., Shin, J. N. et al.:Receptor activator of NF-κBrecruits multiple TRAF family adaptors and activates c-Jun N-terminal kinase. FEBS Lett. 443:297-302, 1999

41) Galibert, L., Tometsko, M. E., Anderson, D. M. et al.:The involvement of multiple tumor necrosis factor receptor(TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-κB, a member of the TNFR superfamily. J. Biol. Chem.273:34120-34127, 1998

42) Wong, B. R., Josien, R., Lee, S. Y. et al.:The TRAF family of signal transducers mediates NF-κB activation by the TRANCE receptor. J. Biol. Chem. 273:28355-28359, 1998

43) Lomaga, M. A., Yeh, W. C., Sarosi, I. et al.:TRAF 6 deficiency results in osteopetrosis and defective interleukin-1, CD 40, and LPS signaling. Genes Dev. 13:1015-1024, 1999

44) Naito, A., Azuma, S., Tanaka, S. et al.:Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF 6-deficient mice. Genes Cells 4:353-362, 1999

45) Kobayashi, N., Kadono, Y., Naito, A. et al.:Segregation of TRAF 6-mediated signaling pathways clarifies its role in osteoclastogenesis. EMBO J. 20:1271-1280, 2001

46) Wong, B. R., Besser, D., Kim, N. et al.:TRANCE, a TNF family member, activates Akt/PKB through asignaling complex involving TRAF 6 and c-Src. Mol. Cell 4:1041-1049, 1999

47) Kotake, S., Udagawa, N, Hakoda, M. et al.:Activated human T cells directly induce osteoclastogenesis from human monocytes:possible role of T cells in bone destruction in rheumatoid arthritis patients. Arthritis Rheum. 44:1003-1012, 2001

48) Teng, Y. T., Nguyen, H., Gao, X. et al.:Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J. Clin. Invest. 106:R 59-R 67, 2000

49) Takayanagi, H., Ogasawara, K., Hida, S. et al.:T-cell-mediated regulation of osteoclastogenesis by signaling cross-talk between RANKL and IFN-γ. Nature 408:600-605, 2000

50) Jimi, E., Nakamura, I., Duong, L. T. et al.:Interleukin 1 induces multinucleation and bone-resorbing activity of osteoclasts in the absence of osteoblasts/stromal cells. Exp. Cell Res. 247:84-93, 1999

51) Kobayashi, K., Takahashi, N., Jimi, E. et al.:Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J. Exp. Med. 191:275-286, 2000

52) Azuma, Y., Kaji, K., Katogi, R. et al.:Tumor necrosis factor-α induces differentiation of and bone resorption by osteoclasts. J. Biol. Chem. 275:4858-4864, 2000

53) Lam, J., Takeshita, S., Barker, J. E. et al.:TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J. Clin. Invest. 106:1481-1488, 2000

54) Takeda, K., Akira, S.:Roles of Toll-like receptors in innate immune responses. Genes Cells 9:733-742, 2000

55) Suda, K., Woo, J. T., Takami, M. et al.:Lipopolysaccharide supports survival and fusion of preosteoclasts independent of TNF-α, IL-1, and RANKL. J. Cell Physiol. 190:101-107, 2002

56) Sells Galvin, R. J., Gatlin, C. L, Horn, J. W. et al.:TGF-α enhances osteoclast differentiation in hematopoietic cell cultures stimulated with RANKL and M-CSF. Biochem. Biophys. Res. Commun. 265:233-239, 1999

57) Fuller, K., Lean, J. M., Bayley, K. E. et al.:A role for TGFβ(1) in osteoclast differentiation and survival [In Process Citation]. J. Cell Sci. 113:2445-2453, 2000

58) Itoh, K., Udagawa, N., Katagiri, T. et al.:Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-κB ligand. Endocrinology 142:3656-3662, 2001

59) Quinn, J. M., Itoh, K., Udagawa, N. et al.:Transforming growth factor β effects on osteoclast differentiation via direct and indirect actions. J. Bone Miner. Res. 16:1787-1794, 2001

P.62 掲載の参考文献

1) Dickinson, I. R.:Bone, in Connective Tissue and Its Heritable Disorders. (Royce, P. M. and Stein-mann, B. eds.) Wiley-liss Inc, 1993, p. 249-285

2) ver der Rest, M., Garrone, R.:Collagen family of protein. FASEB J. 5:2814-2823, 1991

3) Albert, B., Bray, D., Lewis, J. et al.:Cell junction, cell adhesion, and the extracellular matrix, in Molecular Biology of the Cell. Garlan, New York, London, 1994, p. 949-1010

4) Kivirikko, K.I.:Collagens and their abnormalities in a wide spectrum of diseases. Ann. Med. 25:113-126, 1993

5) Sillence, D., Senn, A., Danks, D.:Genetic heterogeneity in osteogenesis imperfecta. J. Med. Gen. 16:101-116, 1979

6) Willing, M. C., Cohn, D. H., Byers, P. H.:Frameshift mutation near the 3'end of the COL1A1 gene of type I collagen predicts an elongated pro α1(1) chain and results in osteogenesis imperfecta type I. J. Clin. Invest. 85:282-290, 1990

7) Shapiro, J. R., Primorac, D., Rowe, D. W.:Osteogenesis Imperfecta:Current Concepts, in Principles of Bone Biology. (Bilezikian, J. P. ed.) Academic Press, 1996, p. 889-902

8) Boedtker, H., Finer, M., Aho, S.:The structure of the chick α2 collagen gene. Ann. N. Y. Acad. Sci. 460:85-116, 1985

9) Ramirez, E, de Wet, W.:Molecular biology of the human fibrillar collagen genes. Ann. N. Y. Acad. Sci. 543:109-116, 1985

10) Sandell, L. J., Boyd, C. D.:Conserved and divergent sequence and functional elements within collagen gene, in Extracellular Matrix Genes. (Sandell L.J., Boyd C.D. eds.) Academic Press, New York, 1990, p. 1-56

11) Rossert, J., de Crombrugghe, B.:In Principles of Bone Biology. (Bilezikian, J. P. ed.) Academic Press, San Diego, 1996, p. 127-142

12) Solomon, E., Hiorns, L., Sheer, D. et al.:Confirmation that the type l collagen gene on chromosome 17 is COL1A1 using a human genomic probe. Ann. Hum. Genet. 48:39-42, 1984

13) Henderson, A. S., Myers, J. C., Ramirez, F.:Localization of human 2(I) collagen gene (COL1A2) to chromosome 7q22. Cytogenet. Cell Genet. 36:586-587, 1983

14) Fleischmajer, R., Olsen, B. R., Kuhn, K. et al:Structure, molecular biology, and pathology of collagen. Ann. N.Y. Acad. Sci. 580:1-592, 1990

15) Maity, S. N., Golumbek, P.T., Karsenty, G. et al.:Selective activation of transcription by a novel CCAAT binding factor. Science 241:582-585, 1988

16) Hasegawa, T., Zhou, X., Garrett, LA. et al.:Evidence for three major transcription activation elements in the proximal mouse pro α2 (I) collagen promoter. Nucleic. Acids Res. 24:3253-3260, 1996

17) Rossi, P., Karsenty, G., Roberts, A. B. et al.:A nuclear factor 1 binding site mediates the transcriptional activation of a type I collagen promoter by transforming growth factor-β.Cell 52:405-414, 1988

18) Hatamochi, A., de Crombrugghe, B., Krieg, T.:Purification of a novel factor which binds to the mouse α2(I) collagen promoter. FEBS Lett. 327:325-331, 1993

19) Riquet, F. B., Tan, L., Choy, B. K. et al:YY1 is a positive regulator of transcription of the Col1a1 gene. J. Biol. Chem. 276:38665-38672, 2001

20) Karsenty, G., de Crombrugghe, B.:Two different negative and one positive regulatory factors interact with a short promoter segment of the α1(I) collagen gene. J. Biol. Chem. 265:9934-9942, 1990

21) Miao, K., Potter, J.J., Anania, F. A. et al.:Identification of two repressor elements in the mouse α2 (I) collagen promoter. Arch. Biochem. Biophys. 361:7-16, 1999

22) Norman, J.T., Lindahl, G.E., Shakib, K. et al.:The Y-box binding protein YB-1 suppresses collagen α1 (I) gene transcription via an evolutionarily conserved regulatory element in the proximal promoter. J. Biol. Chem. 276:29880-29890, 2001

23) Galera, P., Park, R.W., Ducy, P. et al.:c-Krox binds to several sites in the promoter of both mouse type I collagen genes. Structure/function study and developmental expression analysis. J. Biol. Chem. 271:21331-21339, 1996

24) Hasegawa, T., Takeuchi, A., Miyaishi, O. et al.:Cloning and characterization of a transcription factor that binds to the proximal promoters of the two mouse type I collagen genes. J. Biol. Chem. 272:4915-4923, 1997

25) Hasegawa, T., Takeuchi, A., Miyaishi, O. et al.:PTRF (polymerase I and transcript-release factor) is tissue-specific and interacts with the BFCOL 1 (binding factor of a type-I collagen promoter) zinc-finger transcription factor which binds to the two mouse type-I collagen gene promoters. Biochem. J. 347:55-59, 2000

26) Kern, B., Shen J., Starbuck, M. et al.:Cbfa 1 contributes to the osteoblast-specific expression of type Icollagen genes. J. Biol. Chem. 276:7101-7107, 2001

27) Liska, D.J., Reed, M.J., Sage E.H. et al.:Cell-specific expression of α1(I) collagen-hGH minigenes in transgenic mice. J. Cell Biol. 125:695-704, 1994

28) Rossert, J. A., Chen, S. S., Eberspaecher, H. et al.:Identification of a minimal sequence of the mouse pro-α1(I) collagen promoter that confers high-level osteoblast expression in transgenic mice and that binds a protein selectively present in osteoblast. Proc. Natl. Acad. Sci. USA 93:1027-1031, 1996

29) Terraz, C., Toman, D., Delauche, M. et al.:Delta Ef1 binds to a far upstream sequence of the mouse pro-α1(I) collagen gene and represses its expression in osteoblasts. J. Biol. Chem. 276:37011-37019, 2001

30) Greenwel, P., Inagaki, Y., Hu, W. et al:Sp1 is required for the early response of α2(I) collagen to transforming growth factor-β1. J. Biol. Chem. 272:19738-19745, 1997

31) Zhang, W., Ou, J., Inagaki, Y., et al.:Synergistic cooperation between Sp1 and Smad 3/Smad 4 mediates transforming growth factor β1 stimulation of α2(I)-collagen (COL1A2) transcription. J. Biol. Chem. 275:39237-39245, 2000

32) Inagaki, Y., Truter, S., Tanaka, S. et al.:Overlapping pathways mediate the opposing actions of tumor necrosis factor-α and transforming growth factor-β on α2(I) collagen gene transcription. J. Biol. Chem. 270:3353-3358, 1995

33) Greenwel, P., Tanaka, S., Penkov, D. et al.:Tumor necrosis factor alpha inhibits type 1 collagen synthesis through repressive CCAAT/enhancer-binding proteins. Mol. Cell Biol. 20:912-918, 2000

34) Ghosh, A. K., Yuan, W., Mori, Y. et al.:Antagonistic regulation of type I collagen gene expression by interferon-gamma and transforming growth factor-β. Integration at the level of p 300/CBP transcriptional coactivators. J. Biol. Chem. 276:11041-11048, 2001

35) Jahner, D., Jaenisch, R.:Retrovirus-induced de novo methylation of flanking host sequences correlates with gene inactivity. Nature 315:594-597, 1985

36) Thompson, J. P., Simkevich, C. P., Holness, M. A. et al.:In vitro methylation of the promoter and enhancer of pro a 1(I) collagen gene leads to its transcriptional inactivation. J. Biol. Chem. 266:2549 2556, 1991

37) Sengupta, P.K., Smith, B.D.:Methylation on the initiation region of the first exon suppresses collagen pro-a 2(I) gene transcription. Biochem. Biophys. Acta 1443:75-89, 1998

38) Akai, J., Kimura, A., Hata, R.:Transcriptional regulation of the human type I collagenα2 (COL1A2) gene by the combination of two dinucleotide repeats. Gene 239:65-73, 1999

39) Hata, R., Akai, J., Kimura, A. et al.:Association of functional microsatellites in the human type I collagen α2 chain (COL1A2) gene with systemic sclerosis. Biochem. Biophys. Res. Commun. 272:36-40, 2000

40) 畑隆一郎:I型コラーゲンの遺伝子多型と結合組織の複合遺伝病. 細胞工学 20:592-598, 2001

41) Albert, B., Bray, D., Johnson, A. et al.:Intracellular compartments and transport, in Essential Cell Biology. (Albert, B. ed.) Garland, New York, 1997, p.447-480

42) Hendrick, J.P., Hartl, F.U.:Molecular chaperone function of heat-shock proteins. Ann. Rev. Cell Biol. 62:349-384, 1993

43) Nagata, K., Saga, S., Yamada, K. M.:A major collagen-binding protein of chick embryo fibroblasts is a novel heart shock protein. J. Cell Biol. 103:223-229, 1986

44) Satoh, M., Hirayoshi, K., Yokota, S. et al.:Intracellular interaction of collagen-specific stress protein HSP 47 with newly synthesized procollagen. J. Cell Biol. 133:469-483, 1996

45) Nakai, A., Satoh, M., Hirayama, K. et al.:Involvement of the stress protein HSP 47 in procollagen in the endoplasmic reticulum. J. Cell Biol. 117:903-914, 1992

46) Jain, N., Brickenden, A., Ball, E. H. et al.:Inhibition of procollagen I degradation by colligin:a collagen-binding serpin. Arch. Biochem. Biophys. 314:23-30, 1994

47) Clarke, E.P., Jain, N., Brickenden, A. et al.:Parallel regulation of procollagen I and colligin, a collagen-binding protein and a member of the serine protease inhibitor family. J. Cell Biol. 121:193-199, 1993

48) Masuda, H., Hosokawa, N, Nagata, K.:Expression and localization of collagen-binding stress protein Hsp 47 in mouse embryo development:comparsion with type I and type II collagen. Cell Stress Shaperones 3:256-264, 1998

49) Nagai, N., Hosokawa, M., Itohara, S. et al.:Embryonic lethality of molecular chaperone Hsp 47 knockout mice is associated with defects in collagen biosynthesis. J. Cell Biol. 150:1499-1505, 2000

50) Kivirikko, K.I., Myllyharju, J.:Prolyl 4-hydroxylases and their protein disulfide isomerase subunit. Matrix Biol. 16:357-368, 1998

51) Passoja, K., Rautavuoma, K., Ala-Kokko, Let al:Cloning and characterization of a third human lysyl hydroxylase isoform. Proc. Natl. Acad. Sci. USA 95:10482-10486, 1998

52) Blumenkrantz, N., Assad R., Peterkofsky, B.:Characterization of collagen hydroxylysyl glycosyltransferases as mainly intramembranous microsomal enzymes. J. Biol Chem. 259:854-859, 1984

53) Heikkinen, J., Risteli, M., Wang, C. et al.:Lysyl hydroxylase 3 is a multifunctional protein processing collagen glycosyltransferase activity. J. Biol. Chem. 275:36158-36163, 2000

54) Ruotsalainen, H., Vanhatupa, S., Tampio, M. et al.:Complete genomic structure of mouse lysyl hydroxylase 2 and lysyl hydroxylase 3/collagen glycosyltransferase. Matrix Biol. 20:137-146, 2001

55) McLaughlin, S.H., Bulleid, N.J.:Molecular recognition in procollagen chain assembly. Matrix Biol. 16:369-377, 1998

56) Colige, A., Li, S.W., Sieron, A.L. et al:cDNA cloning and expression of bovine procollagen I N-proteinase:a new member of the superfamily of zinc-metalloproteillases with binding sites for cells and other matrix components. Proc. Natl. Acad. Sci. USA 94:2374-2379, 1997

57) Holima, Y., van der Rest, M., Prockop, D.J.:Type I procollagen carboxyl-terminal protease from chick embryo tendons. Purification and characterization. J. Biol. Chem. 260:15996-16003, 1985

58) Kessler, E., Takahara, K., Brusel, M. et al.:Bone morphogenetic protein-1:the type I procollagen C-proteinase. Science 271:360-362, 1996

59) Li, S. W., Sieron, A. L, Fertala, A. et al.:The C-proteinase that processes procollagens to fibrillar collagens is identical to the protein previously identified as bone morphogenic protein-1. Proc. Natl. Acad. Sci. USA 93:5127-5130, 1996

60) Uzel, M.I., Scott, I.C., Babakhanlou-Chase, H. et al.:Multiple bone morphogenetic protein-1-related mammalian metalloproteinases process prolysyl oxidase at the correct physiological site and control lysyl oxidase activation in mouse embryo fibroblast cultures. J. Biol. Chem. 276:22537-22543, 2001

61) O'Reilly, M.S., Boehm, T.,Shing, Y. et al.:Endostatin:an endogenous inhibitor of angiogenesis and tumor growth. Cell 88:277-285, 1997

62) Petitclerc, E., Boutaud, A., Prestayko, A. et al.:New function for non-collagenous domains of human collagen type IV. J. Biol. Chem. 275:8051-8061, 2000

63) 岡田保典, 橋本学爾:マトリックスメタロプロテアーゼによる細胞外マトリックス代謝と関節破壊. 生化学 73:1309-1321, 2001

64) Bode, W., Reinemer, P., Huber, R. et al.:The X-ray crystal structure of the catalytic domain of human neutrophil collagenase inhibited by a substrate analogue reveals the essentials for catalysis and specificity. EMBO J. 13:1263-1269, 1994

65) Freij, M.P., Diez-Itza, I., Balbin, M. et al.:Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas. J. Biol. Chem. 269:16766-16773, 1994

66) Springman, E.B., Angleton, E.L., Birkedal-Hansen, H. et al.:Multiple models of activation of latent human fibroblast collagenase:evidence for the role of a Cys 73 active-site zinc complex in latency and a cysteine switch mechanism for activation. Proc. Natl. Acad. Sci. USA 87:364-368, 1990

67) Komori, T., Yagi, H., Nomura, S. et al.:Targeted disruption of Cbfa 1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89:755-764, 1997

68) Jimenez, M.J., Balbin, M., Lopez, J.M. et al:Collagenase 3 is a target of Cbfa 1, a transcription factor of the runt gene family involved in bone formation. Mol. Cell Biol. 19:4431-4442, 1999

69) Wang, M., Qin, X., Mudgett, J.S. et al:Matrix metalloproteinase deficiencies affect contact hypersensitivity:stromelysin-1 deficiency prevents the response and gelatinase B deficiency pro-longs the response. Proc. Natl. Acad. Sci. USA 96:6885-6889, 1999

70) Vu, T.H., Shipley, J.M., Bergers, G. et al.:MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocyte. Cell 93:411-422, 1998

71) Holmbeck, K., Bianco, P., Caterina, J. et al.:MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 99:81-92, 1999

72) Zhou, Z., Apte, S.S., Soininen, R. et al.:Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc. Natl. Acad. Sci. USA 97:4052-4057, 2000

73) Murate, T., Hayakawa, T.:Multiple functions of tissue inhibitors of metalloproteinases (TIMPs):new aspects in hematopoiesis. Platelets 10:5, 1999

74) Murphy, G., Willenbrock, F:Tissue inhibitors of matrix metalloendopeptidases. Methods Enzymol. 248:496-510, 1995

75) Okada, Y., Gonoji, Y., Naka, K. et al.:Matrix metalloproteinase 9 (92-kD gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells. Pulification and activation of the precursor and enzyme properties. J. Biol. Chem. 267:21712-21719, 1992

76) DeClerck, Y.A., Yean, T.D., Lu, H. S. et al:Inhibition of autoproteolytic activation of interstitial procollagenase by recombinant metalloproteinase inhibitor MI/TIMP-2. J. Biol. Chem. 266:3893-3899, 1991

77) Nomura, S., Hogan, B.L., Wills, A. J. et al.:Developmental expression of tissue inhibitor of metalloproteinase (TIMP) RNA. Development 105:575-583, 1989

78) Waterhouse, P., Denhardt, D. T., Khokha, R.:Temporal expression of tissue inhibitors of metalloproteinases in mouse reproductive tissues during gestation. Mol. Reprod. Dev 35:219-226, 1993

79) Apte, S.S., Hayashi, K., Seldin, M.F. et al.:Gene encoding a novel murine tissue inhibitor of metalloproteinases (TIMP), TIMP-3, is expressed in developing mouse epithelia, cartilage, and muscle, and is located on mouse chromosome 10. Dev. Dyn. 200:177-197, 1994

80) Greene, J., Wang, M., Liu, Y. E. et al.:Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J. Biol. Chem. 271:30375-30380, 1996

81) Yang, T.T., Hawkes, S.P.:Role of the 21-kDa protein TIMP-3 in oncogenic transformation of cultured chicken embryo fibroblasts. Proc. Natl. Acad. Sci. USA 89:10676-10680, 1992

82) Clark, I.M., Powell, LK., Cawston, T. E.:Tissue inhibitor of metalloproteinases (TIMP-1) stimulates the secretion of collagenase from human skin fibroblasts. Biochem. Biophys. Res. Commun. 203:874-880, 1994

83) Kinoshita, T., Sato, H., Okada, A. et al.:TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immobilized on agarose beads. J. Biol. Chem. 273:16098-16103, 1998

84) 早川太郎:TIMPの多彩な機能. 現代医療 32:949-959, 2000

第II章骨代謝マーカーの基礎的事項

P.76 掲載の参考文献

1) 中塚喜義, 三浦雅一 (訳):骨粗鬆症における生化学的骨代謝マーカーの使用に関する方針. Osteoporos. Jpn. 9:71-93, 2001

2) 日本骨粗鬆症学会骨粗鬆症診療における骨粗鬆症マーカーの適正使用に関する指針検討委員会:骨粗鬆症診療における骨代謝マーカーの適正使用ガイドライン2001年度版. Osteoporos. Jpn. 9:113-165, 2001

3) 網野信行, 日高洋:臨床検査に用いられる免疫測定法の種類とエンザイムイムノアッセイの位置づけ. 日本臨牀 53:2107-2111, 1995

4) 黒江謙治, 秩父賢司:RIA法による血中PlCP (I型コラーゲン-C-テロペプチド) の測定. ホルモンと臨床 42:1185-1188, 1994

5) 川口浩, 松本俊夫, 黒川高秀ほか:Monoclonal抗体を用いたtwo-site immunoradiometric assay (IRMA)による血清BGP濃度の測定. ホルモンと臨床38:1291-1296, 1990

6) Hata, K., Tokuhiro, H., Nakatsuka, K, et al:Measurement of bone-specific alkaline phosphate by an immunoselective enzyme assay method. Ann. Clin. Biochem. 33:127-131, 1996

7) 馬場正博:骨吸収マーカーNTxの基礎と骨粗鬆症における臨床的有用性. 生物試料分析 22:121-128, 1999

8) 残間雅秋:EIA法による血清骨型アルカリフォスファターゼ(BAP)の測定. 生物試料分析 22:115-120, 1999

9) Rosano, T.G., Peaston, R.T., Bone, H.G. et al.:Urinary free deoxypyridinoline by chemiluminescence immunoassay:analytical and clinical evaluation. Clin. Chem. 44:2126-2132, 1998

10) Okabe, R., Nakatsuka, K., Inaba, M. et al:Clinical evaluation of the Elecsys B-CrossLaps serum assay, a new assay for degradation products of type I collagen C-telopeptides. Clin. Chem. 47:1410-1414, 2001

P.87 掲載の参考文献

1) Delmas, P. D., Eastell, R., Garnero, P. et al.:for the Commitee of Scientific Advisors of the International Osteoporosis Foundation:The use of biochemical markers of bone turnover in osteoporosis. Osteoporos. Int. 11 (Suppl.6):S2-S17, 2000

2) Hannon, R., Eastell, R.:Preanalytical variability of biochemical markers of bone turnover. Osteoporos. Int. 11 (Suppl.6):S30-S44, 2000

3) Delmas, P.D., Chatelain, P., Malaval, L. et al.:Serum bone GLA-protein in growth hormone deficient children. J. Bone Miner. Res. 1:333-338, 1986

4) Delmas, P.D., Glorieux, F.H., Delvin, E. E. et al.:Perinatal serum bone Gla-protein and vitamin D metabolites in preterm and fullterm neonates. J. Clin. Endocrinol. Metab. 65:588-591, 1987

5) Mora, S., Pitukcheewanont, P., Kaufman, F.R. et al.:Biochemical markers of bone turnover and the volume and the density of bone in children at different stages of sexual development. J. Bone Miner Res. 14:1664-1671, 1999

6) Mora, S., Prinster, C., Proverbio, M. C. et al.:Urinary markers of bone turnover in healthy children and adolescents:age-related changes and effect of puberty. Calcif. Tissue Int. 63:369-374, 1998

7) Blumsohn, A., Hannon, R. A., Wrate, R. et al.:Biochemical markers of bone turnover in girls during puberty. Clin. Endocrinol. (Oxf) 40:663-670, 1994

8) Stepan, J. J., Tesarova, A., Havranek, T. et al.:Age and sex dependency of the biochemical indices of bone remodelling. Clin. Chim. Acta. 151:273-283, 1985

9) Crofton, P.M.:Wheat-germ lectin affinity electrophoresis for alkaline phosphatase isoforms in children:age-dependent reference ranges and changes in liver and bone disease. Clin. Chem. 38:663-670, 1992

10) Saggese, G., Bertelloni, S., Baroncelli, G.I. et al.:Serum levels of carboxyterminal propeptide of type Iprocollagen in healthy children from 1st year of life to adulthood and in metabolic bone diseases. Eur. J. Pediatr. 151:764-768, 1992

11) Marowska, J., Kobylinska, M., Lukaszkiewicz, J. et al.:Pyridinium crosslinks of collagen as a marker of bone resorption rates in children and adolescents:normal values and clinical application. Bone 19:669-677, 1996

12) Bass, S., Delmas, P.D., Pearce, G. et al.:The differing tempo of growth in bone size, mass, and density in girls is region-specific. J. Clin. Invest. 104:795-804, 1999

13) Fatayerji, D., Eastell, R.:Age-related changes in bone turnover in men. J. Bone Miner. Res. 14:1203-1211, 1999

14) Khosla, S., Atkinson, E.J., Melton, LJ. III. et al.:Effects of age and estrogen status on serum parathyroid hormone levels and biochemical markers of bone turnover in women:a population based study. J. Clin. Endocrinol. metab. 82:1522-1527, 1997

15) Yoshimura, N., Hashimoto, T., Sakata, K. et al.:Biochemical markers of bone turnover and bone loss at the lumbar spine and femoral neck. The Taiji study. Calcif. Tissue Int. 65:198-202, 1999

16) Ebeling, P.R., Atley, LM., Guthrie, J.R. et al.:Bone turnover markers and bone density across the menopausal transition. J. Clin. Endocrinol. Metab. 81:3366-3371, 1996

17) Clemens, J.D., Herrick, M.V., Singer, F.R. et al.:Evidence that serum NTx (collagen-type I N telopeptide) can act as an immunochemical marker of bone resorption. Clin. Chem. 43:2058-2063, 1997

18) Rosenquist, C., Fledelius, C., Christgau, S. et al.:Serum CrossLaps One Step ELISA:first application of monoclonal antibodies for measurement in serum of bone related degradation products from C-terminal telopeptides of type I collagen. Clin. Chem. 44:2281-2289, 1998

19) Pratt, J.H., Manatunga, A.K., Peacock, M.:A comparison of the urinary excretion of bone resorptive products in white and black children. J. Lab. Clin. Med. 127:67-70, 1996

20) Henry, Y.M., Eastell, R.:Ethnic and gender differences in bone mineral density and bone turnover in young adults:effect of bone size. Osteoporos. Int. 11:512-517, 2000

21) Kleerekoperm, M., Nelson, D.A., Peterson, E. L. et al.:Body composition and gonadal steroids in older white and black women [published erratum appears in J. Clin. Endocrinol. Metab. 80:1540, 1995]. J. Clin. Endocrinol. Metab. 79:775-779, 1994

22) Bikle, D.D., Ettinger, B., Sidney, S. et al.:Differences in calcium metabolism between black and white men and women. Miner. Electrolyte Metab. 25:178-184, 1999

23) Meier, D. E., Luckey, M. M., Wallenstein, S. et al:Racial differences in pre-and postmenopausal bone homeostasis:association with bone density. J. Bone Miner. Res. 7:1181-1189, 1992

24) Dibba, B., Prentice, A., Laskey, M. A. et al.:An investigation of ethnic differences in bone mineral, hip axis length, calcium metabolism and bone turnover between West African and Caucasian adults living in the United Kingdom. Ann. Hum. Biol. 26:229-242, 1999

25) Bell, NH., Greene, A., Epstein, S. et al.:Evidence for alteration of vitamin D-endocrine system in blacks. J. Clin. Invest. 76:470-473, 1985

26) Han, Z. H., Palnitkar, S., Rao, D. S. et al.:Effects of ethnicity and age or menopause on the remodeling and turnover of iliac bone:implications for mechanisms of bone loss. J. Bone Miner. Res. 12:498-508, 1997

27) Perry, H.M.III., Horowitz, M., Morley, J. E. et al.:Aging and bone metabolism in African American and Caucasian women. J. Clin. Endocrinol. Metab. 81:1108-1117, 1996

28) Baca, E.A., Ulibarri, V.A., Scariano, J.K. et al.:Increased serum levels of N-telopeptides (NTx) of bone collagen in postmenopausal Nigerian women. Calcif. Tissue. Int. 65:125-128, 1999

29) Alekel, D.L., Mortillaro, E., Hussain, E.A. et al.:Lifestyle and biologic contributors to proximal femur bone mineral density and hip axis length in two distinct ethnic groups of premenopausal women. Osteoporos. Int. 9:327-338, 1999

30) Cohen, F.J., Eckert, S., Mitlak, B.H.:Geographic differences in bone turnover:data from a multinational study in healthy postmenopausal women. Calcif. Tissue Int. 63:277-282, 1998

31) 吉村典子, 橋本勉, 森岡聖次ほか:環境の異なる2地域における骨代謝マーカー分布-山村と漁村の比較-. Osteoporos. Jpn. 4:223-226, 1996

32) Garnero, P., Gineyts, E., Riou, J. P. et al.:Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J. Clin. Endocrinol. Metab. 79:780-785, 1994

33) Duda R. J., O'Brien, J. F., Katzman, J. A. et al.:Concurrent assays of circulating bone Gla-protein and bone alkaline phosphatase:effect of sex, age, and metabolic bone disease. J. Clin. Endocrinol. Metab. 66:951-957, 1988

34) Woitge, H. W., Seibel, M. J., Ziegler, R.:Comparison of total and bone-specific alkaline phosphatase in patients with nonskeletal disorders or metabolic bone diseases. Clin. Chem. 42:1796-1804, 1996

35) Schneider, D. L., Barrett-Connor, E. L.:Urinary N-telopeptide levels discriminate normal, osteopenic, and osteoporotic bone mineral density. Arch. Intern. Med. 157:1241-1245, 1997

36) Bettica, P., Taylor, A. K., Talbot, J. et al.:Clinical performance of galactosyl hydroxylysine, pyridinoline, and deoxypyridinoline in postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 81:542-546, 1996

37) Minisola, S., Rosso, R., Romagnoli, E. et al.:Trabecular bone mineral density in primary hyperpara-thyroidism:relationship to clinical presentation and biomarkers of skeletal turnover. Bone Miner. 20:113-123, 1993

38) Christensen, J.O., Svendsen, O.L:Bone mineral in pre-and postmenopausal women with insulin dependent and non-insulin-dependent diabetes mellitus. Osteoporos. Int. 10:307-311, 1999

39) Engler, H., Oettli, R. E., Riesen, W. F.:Biochemical markers of bone turnover in patients with thyroid dysfunctions and in euthyroid controls:a cross-sectional study. Clin. Chim. Acta. 289:159-172, 1999

40) Garnero, P., Vassy, V., Bertholin, A. et al.:Markers of bone turnover in hyperthyroidism and the effects of treatment. J. Clin. Endocrinol. Metab. 78:955-959, 1994

41) Pantazi, H., Papapetrou, P. D.:Changes in parameters of bone and mineral metabolism during therapy for hyperthyroidism. J. Clin. Endocrinol. Metab. 85:1099-1106, 2000

42) Miyakawa, M., Tsushima, T., Demura, H.:Carboxy-terminal propeptide of type I procollagen (PICP) and carboxy-terminal telopeptide of type I collagen (ICTP) as sensitive markers of bone metabolism in thyroid disease. Endocr. J. 43:701-708, 1996

43) Arbault, P., Grimaux, M., Pradet, V. et al.:Assessment of urinary pyridinoline excretion with a specific enzyme-linked immunosorbent assay in normal adults and in metabolic bone diseases. Bone 16:461-467, 1995

44) Legovini, P., De Menis, E., Da Rin, G. et al.:Increased serum levels of carboxyterminal propeptide of type I collagen (PICP) in hyperthyroidism. Horm. Metab. Res. 26:334-337, 1994

45) Delmas, P.D., Wilson, D.M., Mann, K.G. et al.:Effect of renal function on plasma levels of bone Gla-protein. J. Clin. Endocrinol. Metab. 57:1028-1030, 1983

46) Oikarinen, A., Autio, P., Vuori, J. et al.:Systemic glucocorticoid treatment decreases serum concentrations of carboxyterminal propeptide of type I procollagen and aminoterminal propeptide of type III procollagen. Br. J. Dermatol. 126:172-178, 1992

47) Jennings, B.H., Andersson, K.E., Johansson, S.A.:Assessment of systemic effects of inhaled glucocorticosteroids:comparison of the effects of inhaled budesonide and oral prednisolone on adrenal function and markers of bone turnover. Eur. J. Clin. Pharmacol. 40:77-82, 1991

48) Hodsman, A.B., Toogood, J.H., Jennings, B. et al.:Differential effects of inhaled budesonide and oral prednisolone on serum osteocalcin. J. Clin. Endocrinol. Metab. 72:530-540, 1991

49) Wolthers, O.D., Juul, A., Hansen, M. et al.:The insulin-like growth factor axis and collagen turnover during prednisolone treatment. Arch. Dis. Child 71:409-413, 1994

50) Gram, J., Junker, P., Nielsen, H. K. et al.:Effects of short-term treatment with prednisolone and calcitriol on bone and mineral metabolism in normal men. Bone 23:297-302, 1998

51) Lems, W.F., Jahangier, ZN., Jacobs, J.W. et al.:Vertebral fractures in patients with rheumatoid arthritis treated with corticosteroids. Clin. Exp. Rheumatol. 13:293-297, 1995

52) Fujita, T., Satomura, A., Hidaka, M. et al.:Acute alteration in bone mineral density and biochemical markres for bone metabolism in nephrotic patients receiving high-dose glucocorticoid and one-cycle etidronate therapy. Calcif. Tissue Int. 66:195-199, 2000

53) Hall, G.M., Spector, T.D., Delmas, P.D.:Markers of bone metabolism in postmenopausal women with rheumatoid arthritis; effects of corticosteroids and hormone replacement therapy. Arthritis Rheum. 38:902-906, 1995

54) Takeshita, N., Seino, Y., Ishida, H. et al.:Increased circulating levels of gamma-carboxyglutamic acid-containing protein and decreased bone mass in children on anticonvulsant therapy. Calcif. Tissue Int. 44:80-85, 1989

55) Valimaki, M. J., Tiihonen, M., Laitinen, K. et al.:Bone mineral density measured by dual-energy X-ray absorptiometry and novel markers of bone formation and resorption in patients on antiepileptic drugs. J. Bone Miner. Res. 9:631-637, 1994

56) Ohishi, T., Kushida, K., Takahashi, M. et al.:Analysis of urinary pyridinoline and deoxypyr-idinoline in patients undergoing long-trem anticonvulsant drug therapy. Eur. Neurol. 36:300-302, 1996

57) Taga, M., Minaguchi, H.:Change in C-terminal cross-linking domain of type I collagen in urine, a new marker of bone resorption, during and after gonadotropin-releasing hormone agonist administration. Eur. J. Endocrinol. 137:167-171, 1997

58) Marshall, L.A., Cain, D.F., Dmowski, W.P. et al.:Urinary N-telopeptides to monitor bone resorption while on GnRH agonist therapy. Obstet. Gynecol. 87:350-354, 1996

59) Mukherjee, T., Barad, D., Turk, R. et al.:A randomized, placebo-controlled study on the effect of cyclic intermittent etidronate therapy on the bone mineral density changes associated with six months gonadotropin-releasing hormone agonist treatment. Am. J. Obstet. Gynecol. 175:105-109, 1996

60) Perry, H. M. III, Jensen, J., Kaiser, F E. et al.:The effects of thiazide diuretics on calcium metabolism in the aged. J. Am. Geriatr. Soc. 41:818-822, 1993

61) Dawson-Hughes, B., Harris, S.:Thiazides and seasonal bone change in healthy postmenopausal women. Bone Miner. 21:41-51, 1993

62) Rico, H., Revilla, M., Villa, LF. et al.:A longitudinal study of total and regional bone mineral content and biochemical markers of bone resorption in patients with idiopathic hypercalciuria on thiazide treatment. Miner. Electrolyte Metab. 19:337-342, 1993

63) Ingle, B.M., Hay, S.M., Bottjer, H.M. et al.:Changes in bone mass and bone turnover following distal forearm fracture. Osteoporos. Int. 10:399-407, 1999

64) Sorva, A., Valimaki, M., Risteli, J. et al.:Serum ionized calcium, intact PTH and novel markers of bone turnover in bedridden elderly patients. Eur. J. Clin. Invest. 24:806-812, 1994

65) Theiler, R., Stahelin, H. B., Kranzlin, M. et al:High bone turnover in the elderly..Arch. Phys. Med. Rehabil. 80:485-489, 1999

66) Lueken, S.A., Arnaud, S.B., Taylor, A.K. et al.:Changes in markers of bone formation and resorption in a bed rest model of weightlessness. J. Bone Miner. Res. 8:1433-1438, 1993

67) Zerwekh, J. E., Ruml, LA., Gottschalk, F. et al.:The effects of twelve weeks of bed rest on bone histology, biochemical markers of bone turnover, and calcium homeostasis in eleven normal subjects. J. Bone Miner. Res. 13:1594-1601, 1998

68) Uebelhart, D., Bernard, J., Hartmann, D. J. et al.:Modifications of bone and connective tissue after orthostatic bedrest. Osteoporos. Int. 11:59-67, 2000

69) van der Wiel, H. E., Lips, P., Nauta, J. et al.:Biochemical parameters of bone turnover during ten days of bed rest and subsequent mobilization. Bone Miner. 13:123-129, 1991

70) Smith, S. M., Nillen, J. L, LeBlanc, A. et al.:Collagen cross-link excretion during space flight and bed rest. J. Clin. Endocrinol. Metab. 83:3584-3591, 1998

71) Lips, P., van Ginkel, F. C., Netelenbos, J. C. et al.:Lower mobility and markers of bone resorption in the elderly. Bone Miner. 9:49-57, 1990

72) Naylor, K. E., Iqbal, P., Fledelius, C. et al:The effect of pregnancy on bone density and bone turnover. J. Bone Miner. Res. 15:129-137, 2000

73) Rodin, A., Duncan, A., Quartero, H. W. et al.:Serum concentrations of alkaline phosphatase isoenzymes and osteocalcin in normal pregnancy. J. Clin. Endocrinol. Metab. 68:1123-1127, 1989

74) Cole, D.E., Gundberg, C. M., Stirk, L.J. et al.:Changing osteocalcin concentrations during pregnancy and lactation:implications for maternal mineral metabolism. J. Clin. Endocrinol. Metab. 65:290-294, 1987

75) Seki, K., Makimura, N., Mitsui, C. et al.:Calcium-regulating hormones and osteocalcin levels during pregnancy:a longitudinal study. Am. J. Obstet. Gynecol. 164:1248-1252, 1991

76) Yamaga, A., Taga, M., Minaguchi, H.:Changes in urinary excretions of C-telopeptide and cross linked N-telopeptide of type I collagen during pregnancy and puerperium. Endocr. J. 44:733-738, 1997

77) Naylor, K. E., Iqbal, P., Fledelius, C. et al:The effect of pregnancy on bone density and bone turnover. J. Bone Miner. Res. 15:129-137, 2000

78) Yamaga, A., Taga, M., Minaguchi, H. et al.:Changes in bone mass as determined by ultrasound and biochemical markers of bone turnover during pregnancy and puerperium:a longitudinal study. J. Clin. Endocrinol. Metab. 81:752-756, 1996

79) Lopez, J. M., Gonzalez, G., Reyes, V. et al.:Bone turnover and density in healthy women during breastfeeding and after weaning. Osteoporos. Int. 6:153-159, 1996

80) Kalkwarf, H. J., Specker, B. L., Ho, M.:Effects of calcium supplementation on calcium homeostasis and bone turnover in lactating women. J. Clin. Endocrinol. Metab. 84:464-470, 1999

81) Kent, G. N., Price, R. I., Gutteridge, D. H. et al.:Human lactation:forearm trabecular bone loss, increased bone turnover, and renal conservation of calcium and inorganic phosphate with recovery of bone mass following weaning. J. Bone Miner. Res. 5:361-369, 1990

82) Sowers, M., Eyre, D., Hollis, B. W. et al.:Biochemical markers of bone turnover in lactating and nonlactating postpartum women. J. Clin. Endocrinol. Metab. 80:2210-2216, 1995

83) Garnero, P., Sornay-Rendu, E., Delmas, P.D.:Decreased bone turnover in oral contraceptive users. Bone 16:499-503, 1995

84) Blumsohn, A., Herrington, K., Hannon, R. A. et al.:The effect of calcium supplementation on the circadian rhythm of bone resorption. J. Clin. Endocrinol. Metab. 79:730-735, 1994

85) Eastell, R., Calvo, M. S., Burritt, M. F. et al.:Abnormalities in circadian patterns of bone resorption and renal calcium conservation in type I osteoporosis. J. Clin. Endocrinol. Metab. 74:487-494, 1992

86) Eastell, R., Simmons, P. S., Colwell, A. et al.:Nyctohemeral changes in bone turnover assessed by serum bone Gla-protein concentration and urinary deoxypyridinoline excretion:effects of growth and ageing. Clin. Sci. (Colch) 83:375-382, 1992

87) Greenspan, S.L., Dresner-Pollak, R., Parker, R.A. et al.:Diurnal variation of bone mineral turnover in elderly men and women. Calcif. Tissz Int. 60:419-423, 1997

88) Hassager, C., Risteli, J., Risteli, L. et al.:Diurnal variation in serum markers of type I collagen synthesis and degradation in healthy premenopausal women. J. Bone Miner. Res. 7:1307-1311, 1992

89) Mautalen, C. A.:Circadian rhythm of urinary total and free hydroxyproline excretion and its relation to creatinine excretion. J. Lab. Clin. Med. 75:11-18, 1970

90) Wichers, M., Schmidt, E., Bidlingmaier, F. et al.:Diurnal rhythm of CrossLaps in human serum. Clin. Chem. 45:1858-1860, 1999

91) Chiu, K. M., Ju, J., Mayes, D. et al:Changes in bone resorption during the menstrual cycle. J. Bone Miner. Res. 14:609-615, 1999

92) Schlemmer, A., Hassager, C., Risteli, J. et al.:Possible variation in bone resorption during the normal menstrual cycle. Acta. Endocrinol. (Copenh) 129:388-392, 1993

93) Nielsen, H.K., Brixen, K., Bouillon, R. et al.:Changes in biochemical markers of osteoblastic activity during the menstrual cycle. J. Clin. Endocrinol. Metab. 70:1431-1437, 1990

94) Zittermann, A., Schwarz, L., Scheld, K. et al.:Physiologic fluctuations of serum estradiol levels influence biochemical markers of bone resorption in young women. J. Clin. Endocrinol. Metab. 85:95-101, 2000

95) Gorai, I., Chaki, O., Nakayama, M. et al.:Urinary biochemical markers for bone resorption during the menstrual cycle. Calcif. Tissue Int. 57:100-104, 1995

96) Gorai, I., Taguchi, Y., Chaki, O. et al.:Serum soluble interleukin-6 receptor and biochemical markers of bone metabolism show significant variations during the menstrual cycle. J. Clin. Endocrinol. Metab. 83:326-332, 1998

97) Woitge, H. W., Scheidt-Nave, C., Kissling, C. et al.:Seasonal variation of biochemical indexes of bone turnover:results of a population-based study. J. Clin. Endocrinol. Metab. 83:68-75, 1998

98) Overgaard, K, Nilas, L., Johansen, J.S. et al.:Lack of seasonal variation in bone mass and biochemical estimates of bone turnover. Bone 9:285-288, 1988

99) Rosen, CJ., Morrison, A., Zhou, H. et al.:Elderly women in northern New England exhibit seasonal changes in bone mineral density and calciotropic hormones. Bone Miner. 25:83-92, 1994

100) Thomsen, K., Eriksen, E.F., Jorgensen, J.C. et al.:Seasonal variation of serum bone GLA protein. Scand. J. Clin. Lab. Invest. 49:605-611, 1989

101) Douglas, A.S., Miller, M.H., Reid, D.M. et al.:Seasonal differences in biochemical parameters of bone remodelling. J.Clint. Pathol. 49:284-289, 1996

102) Joerring, S., Jensen, L.T., Andersen, G.R. et al.:Types I and III procollagen extension peptides in serum respond to fracture in humans. Arch. Orthop. Trauma Surg. 111:265-267, 1992

103) Zaninotto, M., Bernardi, D., Ujka, F. et al:A proposal for standardizing urine collections for bone resorption markers measurement. J. Clin. Lab.. Anal. 12:145-149, 1998

104) Brahm, H., Strom, H., Piehl-AUlin, K. et al.:Bone metabolism in endurance trained athletes:a comparison to population based controls based on DXA, SXA, quantitative ultrasound, and biochemical markers. Calcif Tissue Int. 61:448-454, 1997

105) Bennell, K.L, Malcolm, S.A., Kahn, K.M. et al.:Bone mass and bone turnover in power athletes, endurance athletes, and controls:a 12-month longitudinal study. Bone 20:477-484, 1997

106) Eliakim, A., Raisz, L.G., Brasel, J.A. et al.:Evidence for increased bone formation following a brief endurance-type training intervention in adolescent males. J. Bone Miner. Res. 12:1708-1713, 1997

107) Danz, A. M., Zittermann, A., Schiedermaier, U. et al.:The effect of a specific strength-development exercise on bone mineral density in perimenopausal and postmenopausal women. J. Womens Health 7:701-709, 1998

108) Fujimura, R., Ashizawa, N., Watanabe, M. et al.:Effect of resistance exercise training on bone formation and resorption in young male subjects assessed by biomarkers of bone metabolism. J. Bone Miner. Res. 12:656-662, 1997

109) Lohman, T., Going, S., Pamenter, R. et al.:Effects of resistance training on regional and total bone mineral density in premenopausal women:arandomized prospective study. J. Bone Miner. Res. 10:1015-1024, 1995

110) Menkes, A., Mazel, S., Redmond, R.A. et al.:Strength training increases regional bone mineral density and bone remodeling in middle-aged and older men. J. Appl. Physiol. 74:2478-2484, 1993

111) Ryan, A.S., Treuth, M.S., Hunter, G.R. et al.:Resistive training maintains bone mineral density in postmenopausal women. Calcif. Tissue Int. 62:295-299, 1998

112) Pruitt, L.A., Jackson, R.D., Bartels, R.L. et al.:Weight-training effects on bone mineral density in early postmenopausal women. J. Bone Miner. Res. 7:179-185, 1992

113) Etherington, J., Keeling, J., Bramley, R. et al.:The effects of 10 weeks military training on heel ultrasound and bone turnover. Calcif. Tissue Int. 64:389-393, 1999

114) Franck, H., Beuker, F, Gurk, S.:The effect of physical acitivity on bone turnover ill young adults. Exp. Clin. Endocrinol 98:42-46, 1991

115) Woitge, H.W., Friedmann, B., Suttner, S. et al.:Changes in bone turnover induced by aerobic and anaerobic exercise in young males. J. Bone Miner Res. 13:1797-1804, 1998

116) Ashizawa, N., Ouchi, G., Fujimura, R. et al.:Effects of a single bout of resistance exercise on calcium and bone metabolism in untrained young males. Calcif. Tissue Int. 62:104-108, 1998

117) Thorsen, K., Kristofferson, A., Lorenztzon, R.:The effects of brisk walking on markers of bone and calcium metabolism in postmenopausal women. Calif. Tissue Int. 58:221-225, 1996

118) Gasser, A., Celada, A., Courvoisier, B. et al.:The clinical measurement of urinary total hydroxy-proline excretion. Clin. Chim. Acta. 95:487-491, 1979

119) Baker, A., Turley, E., Bonham, M. P. et al:No effect of copper supplementation on biochemical markers of bone metabolism in healthy adults. Br. J. Nutr. 82:283-290, 1999

120) Doyle, L., Flynn, A., Cashman, K.:The effect of magnesium supplementation on biochemical markers of bone metabolism or blood pressure in healthy young adult females. Eur. J. Clin. Nutr. 53:255-261, 1999

121) Ginty, F., Flynn, A., Cashman, K. D.:The effect of dietary sodium intake on biochemical markers of bone metabolism in young women. Br. J. Nutr. 79:343-350, 1998

122) Whybro, A., Jagger, H., Barker, M. et al.:Phosphate supplementation in young men:lack of effect on calcium homeostasis and bone turn over, Eur. J. Clin. Nutr. 52:29-33, 1998

123) Ginty, F., Flynn, A., Cashman, K.D.:The effect of short-term calcium supplementation on biochemical markers of bone metabolism in healthy young adults. Br. J. Nutr. 80:437-443, 1998

124) Seibel, M.J.:Molecular markers of bone turnover:biochemical, technical and analytical aspects. Osteoporos. Int. 11 (Suppl. 6):S18-S 29, 2000

125) Delmas, P.D., Eastell, R., Garnero, P. et al.:for the Commitee of Scientific Advisors of the International Osteoporosis Foundation (中塚喜義, 三浦雅一翻訳):骨粗鬆症における生化学的骨代謝マーカーの使用に関する方針書. Osteoporos. Jpn. 9:71-93, 2001

P.101 掲載の参考文献

1) Delmas, P. D., Eastell, R., Garnero, P. et al.:The use of biochemical markers of bone turnover in osteoporosis. Osteoporos. Int. 11 (Suppl. 6):S2-S 17, 2000

2) Hannon, R., Eastell, R.:Preanalytical variability of biochemical markers of bone turnover. Osteoporos. Int. 11 (Suppl 6):S30-S 40, 2000

3) 福永仁夫, 曽根照喜, 友光達志ほか:骨代謝マーカーの年齢・性別の基準値. Osteoporos. Jpn. 9:265-271, 2001

4) 市原清志:正常値 (基準値:基準範囲) ・異常値に対する考え方. 広範囲血液・尿科学検査, 免疫学的検査 (上巻). 日本臨床 53 (増刊号):9-28, 1996

5) Garnero, P., Sornay-Rendu, E., Duboeuf, F. et al.:Markers of bone turnover predict post menopausal forearm bone loss over 4 years:the OFELY study. J. Bone Miner. Res. 14:1614-1621, 1999

6) Rosen, C.J., Chesnut, C.H. III, Malinak, N.J.:The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J. Clin. Endocrinol. Metab. 82:1904-1910, 1997

7) 骨粗鬆症診療における骨代謝マーカーの適正使用ガイドライン (2002年度版).

8) Garnero, P., Sornay-Rendu, E., Claustrat, B. et al:Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women:the OFELY study. J. Bone Miner. Res. 15:1526-1536, 2000

9) van Daele, P.L.A., Seibel, M.J., Burger, H. et al.:Case-control analysis of bone resorption markers, disability, and hip fracture risk:the Rotterdam study. BMJ 312:482-483, 1996

10) Garnero, P., Hausher, E., Chapuy, M.C. et al:Markers of bone resorption predict hip fracture in elderly women:the EPIDOS prospective study. J. Bone Miner. Res. 11:1531-1538, 1996

11) Ross, P. D., Kress, B. C., Parson, R. E. et al.:Serum bone alkaline phosphatase and calcaneus bone density predict fractures:aprospective study. Osteoporos. Int. 11:76-82, 2000

12) 川口浩, 松本俊夫, 黒川高秀ほか:Monoclonal抗体を用いたtwo-site immunoradiometric assay(IRMA)による血清BGP濃度の測定. ホルモンと臨床 38:1291-1296, 1990

13) 山本逸雄, 高田政彦, 游逸明ほか:I型コラーゲンのピリヂノリン架橋C端蛋白 (ICTP) の血中濃度の測定-測定キットの基礎的検討と諸種疾患における臨床的検討-. 核医学 30:1411-1417, 1993

14) 福永仁夫, 大塚信昭, 小野志磨人ほか:I型コラーゲン・Cross-linked Carboxyterminal Telopeptide (ICTP) の血中濃度の測定. ホルモンと臨床 41:729-736, 1993

15) 山本逸雄, 高田政彦, 大中恭夫ほか:血中I型プロコラーゲンC端プロペプチド (PICP) の測定. 核医学 30:563-569, 1993

16) 福永仁夫, 大塚信昭, 小野志磨人ほか:I型プロコラーゲンC末端プロペプチド (PICP) 測定用キットによるその血中濃度の測定. 腎と骨代謝 6:237-245, 1993

17) 黒江謙治, 秩父賢司:RIA法による血中PICP (I型プロコラーゲンC末端プロペプチド) の測定. ホルモンと臨床 42:1185-1188, 1994

18) 三木隆巳, 中塚善義, 江澤郁子ほか:EIA法による血清中骨型アルカリフォスファターゼ測定の検討. ホルモンと臨床 45:999-1004, 1997

19) 中外製薬社内データ

20) 小泉満, 山田康彦, 滝口智洋ほか:転移性骨腫瘍診断における骨吸収マーカー (ICTP) と骨形成マーカー (PICP) の役割. 核医学 33:77-84, 1996

21) 高見博:三菱化学ビーシーエル, 持田製薬資料

22) 山本逸雄, 森田陸司, 小西淳二ほか:新しい骨吸収マーカーNTxの転移性骨腫瘍マーカーとしての臨床的有用性の検討一骨シンチグラフィ, および他の骨代謝マーカーとの比較試験一. 核医学 32:501-510, 1995

23) 折茂肇, 森田陸司, 山本逸雄ほか:EIA法による尿中デオキシピリジノリンの代謝性骨疾患における有用性の検討. ホルモンと臨床 44:873-883, 1996

24) 小泉満, 高橋俊二, 相羽恵介ほか:転移性骨腫瘍臨床評価における骨吸収マーカー尿中デオキシピリジノリンの有用性の検討. ホルモンと臨床 44:1011-1023, 1996

25) 小泉満, 高橋俊二, 相羽恵介ほか:転移性骨腫瘍臨床評価における骨形成マーカー血清骨型アルカリフォスファターゼの有用性の検討. ホルモンと臨床 45:1091-1098, 1997

P.107 掲載の参考文献

1) Seibel,M.J.:Molecular markers of bone turnover:biochemical,technical and analytical aspects.Osteoporos.Int. 11(Suppl.6):S18-S29,2000

2) Hannon,R.,Eastell,R.:Preanalytical variability of biochemical markers of bone tunrover.Osteoporos Int. 11(Suppl.6):S30-S40,2000

3) Hannon,R.,Blumsohn,A.,Naylor,K.et al:Response of biochemical markers of bone turnover to hormone replacement therapy :impact of biological variability.J.Bone Miner.Res. 13:1124-1133,1998

4) Machado,A.B.C.,Hannon,R.,Eastell,R.:Monitoring alendronate therapy for osteoporosis.J.Bone Miner.Res. 14:602-608,1999

第III章骨代謝マーカーの各論: 臨床応用

P.115 掲載の参考文献

1) Hauschka, P.V., Lian, J.B., Cole, D.E. et al.:Osteocalcin and matrix Gla protein:vitamin K-dependent proteins in bone. Physiol Rev. 69:990-1047,1989

2) Price, P.A., Williamson, M.K., Lothringer, J.W.:Origin of the vitamin K-dependent bone protein found in plasma and its clearance kidney and bone.J.Biol. Chems.256:12760-12766,1981

3) Price, P.A., Williamson, M.K.:Effects of warfarin on bone. Studies on the K-dependent protein of rat bone.J Biol. Chems. 256:12754-12759,1981

4) Hosoda, K., Eguchi, H., Nakamoto, T. et al.:Sandwich immunoassay for intact osteocalcin.Clin. Chem. 38:2233-2238, 1992

5) Ducy, P., Desbois, C., Boyce, B. et al.:Increased bone formation in osteocalcin-deficient mice. Nature 382:448-452, 1996

6) Caren, M., Gundberg, C.:Biology, physiology and clinical chemistry of osteocalcin.J. Clin. Ligand Assay 21:128-138, 1998

P.132 掲載の参考文献

1) Stein, G.S., Lian, J.B.:Molecular mechanisms mediating proliferation/differentiation interrelationships during progressive development of the osteoblast phenotype. Endocr. Rev. 14:424-442, 1993

2) Risteli, J., Niemi, S., Kauppila, S. et al.:Collagen propeptides as indicators of collagen assembly. Acta. Orthop. Scand. 266 (Suppl.):183-188, 1995

3) Pavlin, D., Lichtler, A.C., Bedalov, A. et al.:Differential utilization of regulatory domains within the α1(I) collagen promoter in osseous and fibroblastic cells. J. Cell Biol. 116:227-236, 1992

4) Rossert, J., Eberspaecher, H., de Crombrugghe, B.:Separate cis-acting DNA elements of the mouse pro α1(I) collagen promoter direct expression of reporter genes to different type I collagen-producing cells in transgenic mice. J. Cell Biol. 129:1421-1432, 1995

5) Rossert, J.A., Chen, S.S., Eberspaecher, H. et al.:Identification of a minimal sequence of the mouse pro α1(1) collagen promoter that confers high-level osteoblast expression in transgenic mice and that binds a protein selectively present in osteoblasts. Proc. Natl. Acad. Sci. USA 93:1027-1031, 1996

6) Kessler, E., Takahara, K., Biniaminov, L. et al.:Bone morphogenetic protein-1:the type I procollagen C-proteinase. Science 271:360-362, 1996

7) Smedsrod, B., Melkko, J., Risteli L. et al.:Circulating C-terminal propeptide of type I procollagen is cleared mainly via the mannose receptor in liver endothelial cells. Biochem. J. 271:345-350, 1990

8) Melkko, J., Hellevik, T., Risteli, L. et al.:Clearance of NH 2-terminal propeptides of types I and III procollagen is a physiological function of the scavenger receptor in liver endothelial cells. J. Exp. Med. 179:405-412, 1994

9) 山本逸雄, 高田政彦, 大中恭夫ほか:血中I型コラーゲンC末端プロペプチド (PICP) の測定. 核医学 30:563-569, 1993

10) 黒江謙治, 秩父賢司:RIA法による血中PICP (I型プロコラーゲンC末端プロペプチド) の測定. ホルモンと臨床 42:1185-1188, 1994

11) 廣田桂子, 栗本文彦, 畠啓視ほか:RIA法による血清intactPINP (I型プロコラーゲンN末端プロペプチド) 測定の基礎的検討. ホルモンと臨床 45:431-435, 1997

12) 曽根照喜, 吉川邦彦, 玉田勉ほか:RIA法による血清intactPINP (I型プロコラーゲンN末端プロペプチド) 測定の臨床的有用性. ホルモンと臨床 49:1133-1138, 2001

13) Melkko, J., Niemi, S., Risteli, L. et al.:Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clin. Chem. 36:1328-1332, 1990

14) Melkko, J., Kauppila, S., Niemi, S. et al.:Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin. Chem. 42:947-954, 1996

15) Hassager, C., Risteli, J., Risteli, L. et al.:Diurnal variation in serum markers of type I collagen synthesis and degradation in healthy premenopausal women. J. Bone Miner. Res. 7:1307-1311, 1992

16) Pedersen, B. J., Schlemmer, A., Rosenquist, C. et al.:Circadian rhythm in type I collagen formation in postmenopausal women with and without osteopenia. Osteoporos. Int. 5:472-477, 1995

17) Tahtla, R., Sairanen, S., Matti, J.V.:Effect of haemolysis on the concentration of type I procollagen aminoterminal propeptide in serum (s-P I NP);diurnal variation of s-P I NP. Hormones & Markers, Newsletter 2000 (Orion Diagnostica):14-15, 2000

18) Kubo, T., Tanaka, H., Inoue, M. et al.:Serum levels of carboxyterminal propeptide of type I procollagen and pyridinoline crosslinked telopeptide of type I collagen in normal children and children with growth hormone (GH) deficiency during GH therapy. Bone 17:397-401, 1995

19) Tahtla, R., Turpeinen, M., Sorva, R. et al.:The aminoterminal propeptide of type I procollagen:evaluation of a commercial radioimmunoassay kit and values in healthy subjects. Clin. Biochem. 30:35-40, 1997

20) Hannon, R., Eastell, R.:Preanalytical variability of biochemical markers of bone turnover. Osteoporos. Int. 11 (Suppl. 6):S30-S 44, 2000

21) Peris, P., Alvarez, L., Monegal, A. et al.:Biochemical markers of bone turnover after surgical menopause and hormone replacement therapy. Bone 25:349-353, 1999

22) Gorai, I., Chaki, O., Nakayama, M. et al.:Urinary biochemical markers for bone resorption during the menstrual cycle. Calcif. Tissue Int. 57:100-104, 1995

23) Zittermann, A., Schwarz, I., Scheld, K. et al.:Physiologic fluctuations of serum estradiol levels influence biochemical markers of bone resorption in young women. J. Clin. Endocrinol. Metab. 85:95-101, 2000

24) Cross, N.A., Hillman, L.S., Allen, S.H. et al.:Calcium homeostasis and bone metabolism during pregnancy, lactation, and postweaning:a longitudinal study. Am. J. Clin. Nutr. 61:514-523, 1995

25) Naylor, K.E., Iqbal, P., Fledelius, C. et al.:The effect of pregnancy on bone density and bone turnover. J. Bone Miner. Res. 15:129-137, 2000

26) Zerwekh, J. E., Ruml, LA., Gottschalk, F. et al.:The effects of twelve weeks of bed rest on bone histology, biochemical markers of bone turnover, and calcium homeostasis in eleven normal subjects. J. Bone Miner. Res. 13:1594-1601, 1998

27) Sorva, A., Tahtla, R., Risteli, J. et al.:Familial high serum concentrations of the carboxyl-terminal propeptide of type I procollagen. Clin. Chem. 40:1591-1593, 1994

28) Clohisy, D.R., Bar-Shavit, Z., Chappel, J.C. et al.:1,25-Dihydroxyvitamin D3 modulates bone marrow macrophage precursor proliferation and differentiation. Up-regulation of the mannose receptor. J. Biol. Chem. 262:15922-15929, 1987

29) Shepherd, V.L, Konish, M.G., Stahl, P.:Dexamethasone increases expression of mannose receptors and decreases extracellular lysosomal enzyme accumulation in macrophages. J.Biol. Chem. 260:160-164, 1985

30) Schreiber, S., Blum, J.S., Chappel, J. C. et al.:Prostaglandin E specifically upregulates the expression of the mannose-receptor on mouse bone marrow-derived macrophages. Cell Regul. 1:403-413, 1990

31) Ebeling, P.R., Peterson, J.M., Riggs, B.L:Utility of type I procollagen propeptide assays for assessing abnormalities in metabolic bone diseases. J. Bone Miner. Res. 7:1243-1250, 1992

32) Legovini, P., De Menis, E., Da Rin, G. et al.:Increased serum levels of carboxyterminal propeptide of type I collagen (P I CP) in hyperthyroidism. Horm. Metab. Res. 26:334-337, 1994

33) Miyakawa, M., Tsushima, T., Demura, H.:Carboxy-terminal propeptide of type I procollagen (P ICP) and carboxy-terminal telopeptide of type I collagen (I CTP) as sensitive markers of bone metabolism in thyroid disease. Endocr. J. 43:701-708, 1996

34) Bonnin, M.R., Moragues, C., Nolla, J.M. et al:Evaluation of circulating type I procollagen propeptides in patients with Paget's disease of bone. Clin. Chem. Lab. Med. 36:53-55, 1998

35) Delmas P.D.:Biochemical markers of bone turnover in Paget's disease of bone. J. Bone Miner. Res. 14:66-69, 1999

36) Alvarez, L., RicOs, C., Peris, P. et al:Components of biological variation of biochemical markers of bone turnover in Paget's bone disease. Bone 26:571-576, 2000

37) Koizumi, M., Yonese, J., Fukui, I. et al:The serum level of the amino-terminal propeptide of type I procollagell is a sensitive marker for prostate cancer metastasis to bone. B.J.U. Int. 87:348-351, 2001

38) Papatheofanis, F. J.:Serum P I CP as a bolle formation marker in 89 Sr and external beam radiotherapy of prostatic bony metastases. Br. J. Radiol. 70:594-598, 1997

39) Nakashima, J., Sumitomo, M., Miyajima, A. et al.:A transient increase in serum procollagen I carboxyterminal peptide following effective trcatment in prostate cancer patients with bone metastases. Urol.Int. 58:236-238, 1997

40) Garnero, P.:Markers of bone turnover for the prediction of fracture risk. Osteoporos. Int. 11 (Suppl. 6):S55-S65, 2000

41) Scariano, J.K., Glew, R.H., Bou-Serhal, C.E. et al:Serum levels of cross-linked N-telopeptides and aminoterminal propeptides of type I collagen indicate low bone mineral density in elderly women. Bone 23:471-477, 1998

42) Rogers, A., Ilannon, R.A., Eastell, R.:Biochemical markers as predictors of rates of bone loss after menopause. J. Bone Miner. Res. 15:1398-1404, 2000

43) Garnero, P., Sornay-Rendu, E., Claustrat, B. et al.:Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women:the OFELY study. J.. Bone Miner. Res. 15:1526-1536, 2000

44) Akesson, K., Ljunghall, S., Jonsson, B. et al.:Assessment of biochemical markers of bone metabolism in relation to the occurrence of fracture:a retrospective and prospective population-based study of women. J. Bone Miner. Res. 10:1823-1829, 1995

45) Delmas, P. D.:Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs. Osteoporos. Int. 11 (Suppl. 6):S66-S 76, 2000

46) Oikarinen, A., Autio, P., Vuori, J. et al.:Systemic glucocorticoid treatment decreases serum concentrations of carboxyterminal propeptide of type I procollagen and aminoterminal propeptide of type III procollagen. Br. J. Dermatol. 126:172-178, 1992

47) Cosman, F., Nieves, J., Woelfert, L. et al.:Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women. J. Bone Miner. Res. 13:1051-1055, 1998

48) Savolainen, E.R., Goldberg, B., Leo, M.A. et al.:Diagnostic value of serum procollagen peptide measurements in alcoholic liver disease.. Alcohol. Clin. Exp.Res. 8:384-389, 1984

49) Niemela, O., Blake, J.E., Orrego, H.:Serum type I collagen propeptide and severity of alcoholic liver disease. Alcohol. Clin. Exp. Res. 16:1064-1067, 1992

50) Guanabens, N., Pares, A., Alvarez, L. et al.:Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis. J. Bone Miner. Res. 13:731-738, 1998

51) Kikuchi, K., Ihn, H., Sato, S. et al.:Serum concentration of procollagen type I carboxyterminal propeptide in systemic sclerosis.. Arch. Dermatol. Res. 286:77-80, 1994

52) Hunzelmann, N, Risteli, J., Risteli, L. et al:Circulating type I collagen degradation products:a new serum marker for clinical severity in patients with scleroderma?Br. J. Dermatol. 139:1020-1025, 1998

53) Scheja, A., Wildt, M., Wollheim, F.A. et al.:Circulating collagen metabolites in systemic sclerosis. Differences between limited and diffuse form and relationship with pulmonary involvement. Rheumatology (Oxford) 39:1110-1113, 2000

54) Ogawa, K., Naritaka, Y., Katsube, T. et al.:Clinical studies of type-I procollagen carboxyterminal peptide in serum of patients with gastric cancer:comparison with CEA and CA 19-9. J. Gastroenterol. 29:250-256, 1994

P.144 掲載の参考文献

1) 高橋正哲:骨吸収マーカー. 臨床病理 44:415-422, 1996

2) Fujimoto, D., Akiba, K., Nakamura, N.:Isolation and characterization of a fluorescent material in bovine Achilles tendon collagen. Biochem. Biophys. Res. Commun. 76:1124-1129, 1977

3) Ogawa, T., Ono, T., Tsuda, M. et al:A novel flour in insoluble collagen:a crosslinking moiety in collagen molecule. Biochem. Biophys. Res. Commun. 107:1252-1257, 1982

4) 高橋正哲:骨代謝マーカーによる骨代謝の評価. Clinical Calcium 7:1345-1350, 1997

5) Gunja-Smith, Z., Boucek, R.J.:Collagen cross-linking compounds in human urine. Biochem. J. 197:759-762, 1981

6) Black, D., Duncan, A., Robins, S.P.:Quantative analysis of the pyridinium crosslinks of collagen in urine using ion-paired, reversed phase, high-performance liquid chromatography. Anal. Biochem. 169:197-201, 1988

7) Pratt, D. A., Daniloff, Y., Duncan, A. et al.:Automated analysis of the pyridinium crosslinks of collagen in tissue and urine using solid-phase extraction and reversed-phase high-performance liquid chromatography.. Anal. Biochem. 207:168-175, 1992

8) Seyedin, S.M., Kung, V.T., Daniloff, Y.N. et al.:Immunoassay for urinary pyridinoline:the new marker of bone resorption. J. Bone Miner. Res. 8:635-641, 1993

9) Ohishi, T., Takahashi, M., Kushida, K. et al:Age-related changes of urinary pyridinoline and deoxypyridinoline in Japanese subjects. Clin. Invest. Med. 16:319-325, 1993

10) Kawana, K., Kushida, K., Takahashi, M. et al.:The effect of menopause on biochemical markers and ultrasound densitometry in healthy females. Calcif. Tissue Int. 55:420-425, 1994

11) 高橋正哲, 大石強, 串田一博ほか:尿中ピリジノリン, デオキシピリジノリン測定の臨床応用. Clinical Calcium 3:588-592, 1993

12) Oikawa, M., Kushida, K., Takahashi, M. et al.:Bone turnover and cortical bone mineral density in the distal radius in patients with hyperthyroidism being treated with antithyroid drugs for various periods of time. Clin. Endcrinol. 50:171-176, 1999

13) Robins, S. P.:An enzyme-linked immunoassay for the collagen cross-link pyridinoline. Biochem. J. 207:617-620, 1982

14) Fujimoto, D., Suzuki, M., Uchiyama, A. et al:Analysis of pyridinoline, a cross-linking compound of collagen fibers in human urine. J. Biochem. 94:1133-1136, 1983

15) 高橋正哲, 串田一博, 井上哲郎:ピリジノリンおよびピリジノリン含有テロペプチド (ICTP) の変形性関節症, 慢性関節リウマチにおける軟骨代謝マーカーとしての意義. 関節マーカー. (岩田久, 新名正由編) メディカルレビュー社, 東京, 1997, p. 265-273

16) Seibel, M.J., Duncan, A., Robins, S.P.:Urinary hydroxy-pyridinium crosslinks provide indices of cartilage and bone involvement in arthritic diseases. J. Rheumatol. 16:964-970, 1989

17) Greenwald, R.A., Moak, S.A., Golub, L.M.:Low dose doxycycline inhibits pyridinoline excretion in selected patients with rheumatoid arthritis. Ann. N.Y. Acad. Sci. 732:419-421, 1994

18) Kollerup, G., Hansen, M., Horslev-Petersen, K.:Urinary hydroxypyridinium cross-links of collagen in rheumatoid arthritis. Relation to disease activity and effects of methylpredonisolone. Br. J. Rheumatol. 33:816-820, 1994

19) MacDonald, A.G., McHenry, P., Robins, S.P. et al.:Relationship of urinary pyridinium crosslinks to disease extent and activity in osteoarthritis. Br. J. Rheumatol 33:16-19, 1994

20) Aoshima, H., Kushida, K., Takahashi, M. et al.:Circadian variation of urinary type I collagen cross-linked C-telopeptide and free and peptide-bound forms of pyridinium crosslinks. Bone 22:73-78, 1998

21) Takahashi, M., Kushida, K., Hoshino, H. et al.:Concentrations of pyridinoline and deoxypyridinoline in the joint tissues from osteoarthritis and rheumatoid arthritis.. Ann. Rheum. Dis. 55:324-327, 1996

P.156 掲載の参考文献

1) 日本骨粗鬆症学会:骨粗鬆症診療における骨代謝マーカーの適正使用ガイドライン (2001年度版). Osteoporos. Jpn. 9:255-264, 2001

2) Eyre, D.R.:Bone biomarkers as tools in osteoporosis management. Spine 22:17S-24S, 1997

3) Eyre, D.R.:The specificity of collagen cross-links as markers of bone and connective tissue degradation. Acta. Orthop. Scand. 266 (Suppl.):166-170, 1995

4) Hanson, D.A., Eyre, D.R.:Molecular site specificity of pyridinoline and pyrrole cross-links in type I collagen of human bone. J. Biol. Chem. 271:26508-26516, 1996

5) Apone, S., Lee, M. Y., Eyre, D. R.:Osteoclasts generate cross-linked collagen N-telopeptides (NTx) but not free pyridinolines when culture on human bone. Bone 21:129-136, 1997

6) Atley, L. M., Mort, J. S., Lalumiere, M. et al.:Proteolysis of human bone collagen by cathepsin K:characterization of the cleavage sites generating the cross-linked N-telopeptide neoepitope. Bone 26:241-247, 2000

7) Colwell, A., Eastell, R.:The renal clearance of free and conjugated pyridinium crosslinks of collagen. J. Bone Miner Res. 11:1976-1980, 1996

8) Robins, S.P., Woitge, H., Hesley, R. et al.:Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J. Bone Miner. Res. 9:1643-1649, 1994

9) Eyre, D.R., Van Ness, K., Koob, T.J.:Quantitation of hydroxypyridinium crosslinks in collagen by high performance liquid chromatography. Anal. Biochem. 137:380-388, 1984

10) Looker, A. C., Bauer, C.H, Chesnut, III, C.H. et al:Clinical use of biochemical markers of bone remodeling:curent status and future directions. Osteoporos. Int. 11:467-480, 2000

11) Delmas, P.D., Eastell, R., Garnero, P. et al.:The use of biochemical markers of bone turnover in osteoporosis. Osteoporos. Int. 11 (Suppl. 6):S2-S 17, 2000

12) Miller, P.D., Baran, D.T., Bilezikian, J.P. et al.:Practical clinical application of biochemical markers of bone turnover. J. Clin. Densitom. 2:323-342, 1999

13) Ju, H-S J., Leung, S., Brown, B. et al.:Comparison of analytical performance and biological variability of three bone resorption assays. Clin. Chem. 43:1570-1576, 1997

14) Hannon, R., Blumsohn, A., Naylor, K. et al:Response of biochemical markers of bone turnover to hormone replacement therapy:impact of biological variability. J. Bone Miner. Res. 13:1124-1133, 1998

15) Rosen, H.N., Moses, A.C., Garber, J. et al.:Utility of biochemical markers of bone turnover in the follow-up of patients treated with bisphosphonates. Calcif. Tissue Int. 63:363-368, 1998

16) Braga, de C.M.A., Hannon, R., Eastell, R.:Monitoring alendronate therapy for osteoporosis. J. Bone Miner. Res. 14:602-608, 1999

17) Clowes, J A., Hannon, R A., Yap, T.S. et al.:Effect of feeding on bone turnover markers and its impact on biological variability of measurements. Bone 30:886-890, 2002

18) Ravn, P., Hosking, D., Thompson, D. et al.:Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in early postmenopausal intervention cohort of study. J. Clin. Endocrinol. Metab. 84:2363-2368, 1999

19) Bjarnasson, N.H., Christiansen, C.:Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women. Bone 26:561-569, 2000

20) Garnero, P., Gineyts, E., Arbault, P. et al.:Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J. Bone Miner. Res. 10:641-649, 1995

21) Shiraki, M., Kushida, K., Fukunaga, M. et al.:Adouble-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. Osteoporos. Int. 10:183-192, 1999

22) Greenspan, S.L, Parker, R. A., Ferguson, L. et al.:Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women:a randomized clinical trial. J. Bone Miner. Res. 13:1431-1438, 1998

23) Rosen, C.J., Chesnut, C.H., Mallinak, N.J.S.:The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J. Clin. Endocrinol. Metab. 82:1904-1910, 1997

24) Marcus, R., Holloway, L, Wells, B. et al.:The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women:results from the postmenopausal estrogen/progestin interventions (PEPI) trial. J. Bone Miner. Res. 9:1583-1595, 1999

25) Harris, S.T., Gertz, B.J., Genant, H.K. et al.:The effet of short term treatmnet with alendornate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J. Clin. Endocrinol. Metab. 76:1399-1406, 1993

26) Stock, J.L, Bell, N.H., Chesnut, C.H. et al.:Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am. J. Med. 103:291-297, 1997

27) Harris, S.T., Watts, N.B., Genant, H.K. et al:Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis:arandomized controlled trial. JAMA 282:1344-1352, 1999

28) 串田一博, 岸本英彰, 白木正孝ほか:骨粗鬆症患者に対するリセドロネート長期投与時の有効性と安全性の検討. Osteoporos. Jpn. 10:85-96, 2002

29) Bettica, P., Bevilacqua, M., Vago, T. et al.:Short-term variations in bone remodeling biochemical markers:cyclical etidronate and alendronate effects compared. J. Clin. Endocrinol. Metab. 82:3034-3039, 1997

30) Folgelman, L, Herd, R.J.M., Blake, G.M. et al.:Cyclical etidronate therapy for prevention of postmenopausal bone loss:a 1-year open-label follow-up study. Calcif. Tissue Int. 66:346-354, 2000

31) Herd, R.J.M., Balena, R., Blake, G.M. et al.:The prevention of early postmenopausal bone loss by cyclical etidrinate therapy:a 2-year double-blind, placebo-controlled study. Am. J. Med. 103:92-99, 1997

32) 三木隆己, 中弘志:エチドロネート治療における骨代謝マーカー. Osteoporos. Jpn. 9:297-302, 2001

33) Ravn, P., Clemmesen, B., Christiansen, C.:Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women. Bone 24:237-244, 1999

34) 白木正孝:ビタミンKと骨代謝マーカー. Clinical Calcium 11:933-937, 2001

35) Ross, P.D., Knowlton, W.:Rapid bone loss is associated with increased levels of biochemical markers. J. Bone Miner. Res. 13:297-302, 1997

36) Dresner-Pollak, R., Parker, R., Poku, M. et al.:Biochemical markers of bone turnover reflect femoral bone loss in elderly women. Calcif. Tissue Int. 59:328-333, 1996

37) Chaki, O., Yoshikata, I., Kikuchi, R. et al.:The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women. J. Bone Miner. Res. 15:1537-1544, 2000

38) Garnero, P., Hausher, E., Chapuy, M. C. et al.:Markers of bone resorption predict hip fracture in elderly women:the EPIDOS prospective study. J. Bone Miner. Res. 11:1531-1538, 1996

39) Ohnishi, T., Takahashi, M., Kushida, K. et al.:Changes of biochemical markers during fracture healing. Arch. Orthop. Trauma Surg. 118:126-130, 1998

40) 宮坂健, 大井利夫, 小山忠昭ほか:骨粗鬆症性脊椎圧迫骨折における骨吸収マーカーの臨床的検討. 臨整外 36:815-819, 2001

41) Woitge, H. W., Pecherstorfer, M., Li, Y. et al.:Novel serum markers of bone resorption:clinical assessment and comparison with established urinary indices. J. Bone Miner. Res. 14:792-801, 1999

42) Coleman, R.E.:The clinical use of bone resorption markers in patients with malignant bone disease. Cancer 94:2521-2533, 2002

43) Berenson, J.R., Vescio, R., Henick, K. et al.:A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer 91:144-154, 2001

P.168 掲載の参考文献

1) Seyedin, S.M., Kung, V.T., Daniloff, Y.N. et al.:Immunoassay for urinary pyridinoline:the new marker of bone resorption. J. Bone Miner. Res. 8:635-641, 1993

2) Bonde, M., Qvist, P., Fledelius, C. et al.:Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin. Chem. 40:2022-2025, 1994

3) Fledelius, C., Johnsen, A. H., Cloos, P.A.C. et al.:Characterization of urinary degradation products derived from type I collagen. Identification of aβ-isomerized Asp-Gly sequence within the C-terminal telopeptide (α1) region. J. Biol. Chem. 272:9755-9763, 1997

4) Cloos, P.A., Fledelius, C.:Collagen fragments in urine derived from bone resorption are highly racemized and isomerized:a biological clock of protein aging with clinical potential. Biochem. J. 345:473-480, 2000

5) Bonde, M., Fledelius, C., Qvist, P. et al.:Coated-tube radioimmunoassay for C-telopeptides of type Icollagen to assess bone resorption. Clin. Chem. 42:1639-1644, 1996

6) Bonde, M., Garnero, P., Fledelius, C. et al.:Measurement of bone degradation products in serum using antibodies reactive with an isomerized form of an 8 amino acid sequence of the C-telopeptide of type I collagen. J. Bone Miner. Res. 12:1028-1034, 1997

7) Woitge, H.W., Pecherstorfer, M., Li, Y. et al.:Novel serum markers of bone resorption:clinical assessment and comparison with established urinary indices. J. Bone Miner.Res. 14:792-801, 1999

8) Aoshima, H., Kushida, K., Takahashi, M. et al.:Circadian variation of urinary type I collagen crosslinked C-telopeptide and free and peptide bound forms of pyridinium crosslinks. Bone 22:73-78, 1998

9) Schlemmer, A., Hassager, C.:Acute fasting diminishes the circadian rhythm of biochemical markers of bone resorption. Eur. J. Endocrinol. 140:332-337, 1999

10) 星野裕信:骨粗鬆症および閉経前後健常女性における尿中CrossLapsの検討. 新薬と臨床 47:682-688, 1998

11) Garnero, P., Fledelius, C., Gineyts, E. et al.:Decreasedβ-isomerization of the C-terminal telopeptide of type I collagen α1 chain in Paget's disease of bone. J. Bone Miner. Res. 12:1407-1415, 1997

12) Garnero, P., Gineyts, E., Riou, J.P. et al.:Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease. J. Clin. Endocrinol. Metab. 79:780-785, 1994

13) Bonde, M., Qvist, P., Fledelius, C. et al.:Applications of an enzyme immunoass ay for a new marker of bone resorption (CrossLaps):follow-up on hormone replacement therapy and osteoporosis risk assessment. J. Clin. Endocrinol. Metab. 80:864-868, 1995

14) Garnero, P., Sornay-Rendu, E., Duboeuf, F. et al.:Markers of bone tumover predict postmenopausal forearm bone loss over 4 years:the OFELY study. J. Bone Miner. Res. 14:1614-1621, 1999

15) Garnero P., Hausherr, E., Chapuy, M. C. et al:Markers of bone resorption predict hip fracture in elderly women:the EPIDOS prospective study. J. Bone Miner. Res. 11:1531-1538, 1996

16) Garnero, P., Dargent-Molina, P., Hans, D. et al.:Do markers of bone resorption add to bone mineral density and ultrasonographic heel measurement for the prediction of hip fracture in elderly women? The EPIDOS prospective study. Osteoporos.Int. 8:563-569, 1998

17) Bauer, D.C., Sklarin, P.M., Stone, K.L. et al:Biochemical markers of bone turnover and prediction of hip bone loss in older women:the study of osteoporotic fractures. J. Bone Miner. Res. 14:1404-1410, 1999

18) Garnero, P., Sornay-Rendu, E., Claustrat, B. et al.:Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women:the OFELY study. J. Bone Miner. Res. 15:1526-1536, 2000

19) Chapurlat, R. D., Garnero, P., Breart, G. et al.:Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women:the EPIDOS study. Bone 27:283-286, 2000

20) 高橋正哲:骨代謝マーカーの進歩. 4. CTX (クロスラプス), The Bone 12:65-71, 1998

21) Ravn, P., Christensen, J.O., Baumann, M. et al.:Changes in biochemical markers and bone mass after withdrawal of ibandronate treatment:prediction of bone mass changes during treatment. Bone 22:559-564, 1998

22) Fink, E., Cormier, C., Steinmetz, P. et al.:Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy. Osteoporos. Int. 11:295-303, 2000

23) Cooper, C., Stakkestad, J. A., Radowicki, S. et al:Matrix delivery transdermal 17 6-estradiol for the prevention of bone Ioss in postmenopausal women. The International Study Group. Osteoporos. Int. 9:358-366, 1999

24) Delmas, P. D., Hardy, P., Garnero, P.:Monitoring individual response to hormone replacement therapy with bone markers. Bone 26:553-560, 2000

25) Bjarnason, N.H., Christiansen, C.:Early response in biochemical markers predicts long-term response in bone mass during hormone replacement therapy in early postmenopausal women. Bone 26:561-569, 2000

26) Delmas, P.D., Bjarnason, N.H., Mitlak, B.H. et al.:Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 337:1641-1647, 1997

27) Delmas, P. D., Eastell, R., Garnero, P. et al:The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos. Int. 11 (Suppl.6):S2-S 17, 2000

P.179 掲載の参考文献

1) Hanson, D.A., Weis, M. A., Bollen, A. M. et al.:A specific immunoassay for monitoring human bone resorption:quantitation of type I collagen cross-linked N-telopeptides in urine. J. Bone Miner. Res. 7:1251-1258, 1992

2) Apone, S., Lee, M. Y., Eyre, D. R.:Osteoclasts generate cross-linked collagen N-telopeptides (NTx) but not free pyridinolines when cultured on human bone. Bone 21:129-136, 1997

3) Sassi, M.L., Eriksen, H., Risteil, L. et al.:Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen:loss of antigenicity by treatment with cathepsin K. Bone 26:367-373, 2000

4) Blumsohn, A., Herrington, K., Hannon, R.A. et al.:The effect of calcium supplementation on the circadian rhythm of bone resorption. J. Clin. Endocrionol. Metab. 79:730-735, 1994

5) 細井孝之:骨代謝マーカーの生物学的変動と有意変化. Osteoporos. Jpn. 9:283-287, 2001

6) 馬場正博:骨吸収マーカーNTxの基礎と骨粗鬆症における臨床的有用性. 生物試料分析 22:121-128, 1999

7) Gertz, B.J., Clemens, J.D., Holland, S.D. et al.:Application of a new serum assay for type I collagen crosslinked N-telopeptides:assessment of clinical changes in bone turnover with and without alendronate treatment. Calcif Tissue Int. 63:102-106, 1998

8) Clemens, J.D., Herrick, M.V., Singer, F.R. et al.:Evidence that serum NTx (collagen type I N-teropeptides) can act as an immunochemical marker of bone resorption. Clin. Chem. 43:2058-2063, 1997

9) Bollen, A.M., Eyer, D.R.:Bone resorption rates in children monitored by urinary assay of collagen type I crosslinked peptides. Bone 15:31-34, 1994

10) 北正人, 藤井信吾:閉経のバイオロジー. 日老医会誌 37:507-510, 2000

11) Greenspan, S., Rosen, H.N., Parker, R.A. et al.:Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women:a randomized clinical trial. J. Bone Miner. Res. 13:1431-1438, 1998

12) Chesnut, C.H., Bell, N.H., Clark, G.S. et al.:Hormone replacement therapy in postmenopausal women:urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am. J. Med. 102:29-37, 1997

13) Bone, H.G., Greenspan, S.L., McKeever, C. et al.:Alendronate and estrogen effects in post-menopausal women with low bone mineral density. J. Clin. Endocrinol. Metab. 85:720-726, 2000

14) 高見博, 三村孝, 小原孝男ほか:原発性上皮小体機能亢進症における尿中I型コラーゲン架橋N-テロペプチド (NTx) 測定の臨床的意義. ホルモンと臨床 44:321-326, 1996

15) 山本逸雄, 森田陸司, 小西淳二ほか:新しい骨吸収マーカーNTxの転移性骨腫瘍マーカーとしての臨床的有用性の検討. 核医学 32:501-510, 1995

16) Ishida, H., Suzuki, K., Someya, Y. et al:Possible compensatory role of parathyroid hormone-related peptide on maintenance of calcium homeostasis in patients with non-insulin dependent diabetes mellitus. Acta. Endocrinol. 129:519-524, 1993

17) Colemn, R.E., Purohit, O.P., Vinholes, J.J. et al.:High dose pamidronate:clinical and biological effects in metastatic disease. Cancer 80 (Suppl.):1686-1690, 1997

18) Al-Awadhi, A.M., Olusi, S.O. Al-Zaid, N.S. et al.:Urine levels of type I collagen cross-linked N-telopeptides and deoxypyridinoline correlate with disease activity in rheumatoid arthritis. Clin. Exp. Rheumatol. 16:569-572, 1998

19) Suzuki, K., Sugimoto, C., Takizawa, M. et al.:Correlations between bone mineral density and circulating bone metabolic markers in diabetic patients. Diabetes Res. Clin. Pract. 48:185-191, 2000

20) Suzuki, K., Taguchi, Y., Ishida, H. et al.:The evidence for uncoupling between bone formation and resorption in NIDDM patients. Diabetlogia. 40 (Suppl. 1):A581, 1997

21) Williams, J.P., Blair, H.C., McDonald, J. M. et al.:Regulation of osteoclastic bone resorption by glucose. Biochem.Biophys. Res.Commun. 235:646-651, 1997

22) Suzuki, K., Ishida, H., Takeshita, N. et al:Circulating levels of tartrate-resistant acid phosphatase in rat models of non-insulin-dependent diabetes mellitus., J. Diab. Comp. 12:176-180, 1998

23) 鈴木清, 滝澤誠, 板垣英二ほか:糖尿病と骨代謝異常-最近の考え方と問題点-. 栄養学雑誌 57:125-134, 1999

24) 骨粗鬆症診療における骨代謝マーカーの適性使用に関する指針検討委員会編:骨粗鬆症診療における骨代謝マーカーの適性使用ガイドライン (2001年度版). Osteoporos. Jpn. 9:255-264, 2001

25) 鈴木清, 滝澤誠,. 古川尚志ほか:2型糖尿病における破骨細胞機能の評価-血中・尿中type I collagen代謝産物について. 日本骨代謝学会雑誌 18 (Suppl.):184, 2000

26) 紺屋浩之, 浜口朋也, 郡耕介ほか:2型糖尿病男性患者における骨代謝マーカーと骨密度の検討. Osteporos. Jpn. 9:541-543, 2001

27) Pivonello, R., Faggriano, A., Somma, C.D. et al:Effect of a short-term treatment with alendronate on bone density and bone markers in patients with central diabetes insipidus. J. Clin. Endocrinol. Matab. 84:2349-2352, 1999

28) Papapoulos, S.E., Frolich, M.:Prediction of the outcome of treatment of Paget's disease of bone with bisphosphonates from short-term changes in the rate of bone resorption. J. Clin. Endocrinol. Metab. 81:3393-3397, 1996

29) Cooper, D.S.:Thyroid hormone and the skeleton:a bone of contention. JAMA 259:3175, 1988

30) Sato, K., Han, D. C., Fujii, Y. et al.:Thyroid hormone stimulates alkaline phosphatase activity in cultured rat osteoblastic cells (ROS 17/2. 8) through 3,5,3'-triiode-L-thyronine nuclear receptors. Endocrinology 120:1873-1881, 1987

31) Mundy, C.R., Shapiro, J.L., Bandelin, J.G. et al.:Direct stimulatin of bone resorption by thyroid hormones. J. Clin. Invest. 58:529-534, 1976

32) Pandian, M.R., Morgan, C.H., Carlton, E. et al.:Modified immunoradiometric assay of parathyroid hormone-related protein:Clinical application in the differential diagnosis of hypercalcinoma. Clin. Chem. 38:282-288, 1992

33) Jastrup, B., Mosekilde, L., Melsen, F. et al:Serum level of vitamin D metabolites and bone remodeling in hypertyroidism. Metabolism 31:126-130, 1982

34) Macfarlane, I.A., Mawer, E.B., Berry, J. et al.:Vitamin D metabolism in hyperparathyroidism. Clin. Endocrinol. 17:51-59, 1982

35) Mosekilde, L., Christensen, M.S.:Decreased parathyroid function in hyperthyroidism:inter-relationships between serum parathyroid hormone, calcium-phosphorus metabolism and tyroid function. Acta Endocrinol. 84:566-575, 1977

36) Pantazi, H., Papapetrou, P.:Changes in parameter of bone and mineral metabolism during therapy for hyperthyroidism. J. Clin. Endocrinol. Metab. 85:1099-1106, 2000

37) Terpos, E., Palermos, J., Tsinos, K. et al.:Effect of pamidronate administration on makers of bone turnover and disease activity in multiple myeloma. Eur. J. Haematol. 65:331-336, 2000

38) St. Clair, E.W, Moak, S.A., Wilkinson, W.E. et al:Across sectional analysis of 5 different markers of collagen degradation in rheumatoid arthritis. J. Rheumatol. 25:1472-1479, 1998

P.191 掲載の参考文献

1) Calvo, M.S., Eyre, D.R., Gundberg, C.M.:Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev. 17:333-368, 1996

2) 山本逸雄, 高田政彦, 游逸明ほか:I型コラーゲンのピリジノリン架橋C端蛋白 (lCTP) の血中濃度の測定. 核医学 30:1411-1417, 1993

3) 山本逸雄, 三浦裕晃, 森田陸司:ICTP. 骨代謝マーカー. (福永仁夫, 中村利孝, 松本俊夫編) メディカルレビュー社, 東京, 1995, p. 103-111

4) 曽根照喜:ICTP. 骨代謝マーカー. (西沢良記編) 医薬ジャーナル社, 大阪, 2001, p. 58-64

5) 日本骨粗鬆症学会骨粗鬆症診療における骨代謝マーカーの適正使用に関する指針検討委員会:骨粗鬆症診療における骨代謝マーカーの適正使用ガイドライン (2001年度版). Osteoporos. Jpn. 9:113-122, 2001

6) 福永仁夫, 大塚信昭, 小野志磨人ほか:I型コラーゲン・Cross-linked Carboxytemlinal Telopeptide (ICTP) の血中濃度の測定. ホルモンと臨床 41:729-736, 1993

7) Nishi, Y., Atley, L., Eyre, D. E. et al.:Determination of bone markers in pycnodysostosis:effects of cathepsin K deficiency on bone matrix degradation. J. Bone Miner. Res. 14:1902-1908, 1999

8) Sassi, M.L, Eriksen, H., Risteli, L. et al.:Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen:loss of antigenicity by treatment with cathepsin K. Bone 26:367-373, 2000

9) Sairanen, S., Tahtela, R., Laitinen, K. et al.:Nocturnal rise in markers of bone resorption is not abolished by bedtime calcium or calcitonin. Calcif. Tissue Int. 55:349-352

10) Eriksen, E.F., Charles, P., Melsen, F. et al.:Serum markers of type I collagen formation and degradation in metabolic bone disease:correlation with bone histomorphometry. J. Bone Miner. Res. 8:127-132, 1993

11) Hassager, C., Risteli, J., Risteli, L. et al.:Effect of the menopause and hormone replacement therapy on the carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen. Osteoporos. Int. 4:349-352, 1994

12) Hassager, C., Jensen, L.T., Podenphant, J. et al.:The carboxy-terminal pyridinoline cross-linked telopeptide of type I collagen in serum as a marker of bone resorption:the effect of nandrolone decanoate and hormone replacement therapy. Calcif Tissue Int. 54:30-33, 1994

13) Garnero, P., Shih, W.J., Gineyts, E. et al.:Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J. Clin. Endocrinol. Metab. 79:1693-1700, 1994

14) Koizumi, M., Yamada, Y., Takiguchi, T. et al.:Bone metabolic markers in bone metastases. J. Cancer. Res. Clin. Oncol. 121:542-548, 1995

15) 小泉満, 山田康彦, 滝口智洋ほか:転移性骨腫瘍診断における骨吸収マーカー (ICTP) と骨形成マーカー (PICP) の役害, 核医学 33:77-83, 1996

16) Aruga, A., Koizumi, M., Hotta, R. et al.:Usefulness of bone metabolic markers in the diagnosis and

17) Maeda, H., Koizumi, M., Yoshimura, K. et al:Correlation between bone metabolic markers and bone scan in prostate cancer. J. Urol. 157:539-543, 1997

18) Kylmala, T., Tammela, T.L.J., Risteli, L. et al.:Type I collagen degradation product (I CTP) gives information about the nature of bone metastases and has prognostic value in prostate cancer. Br. J. Cancer 71:1061-1064, 1995

19) Tamada, T., Sone, T., Tomomitsu, T. et al.:Biochemical markers for the detection of bone metastasis in patients with prostate cancer:diagnostic efficacy and the effect of hormonal therapy. J. Bone Miner. Metab. 19:45-51, 2001

20) 山本逸雄, 三浦裕晃,. 木上裕輔ほか:骨転移発見における血中I型コラーゲンC端テロペプチドの経時的測定の意義. 核医学 33:423-429, 1996

21) Miura, H., Yamamoto, L, Takada, M. et al.:Diagnostic validity of bone metabolic markers for bone metastases. Endocr.J. 44:751-757, 1997

22) Koizumi, M., Matsumoto, S., Takahashi, S. et al.:Bone metabolic markers in the evaluation of bone scan flare phenomenon in bone metastases of breast cancer. Clin Nucl. Med. 25:15-20, 1999

23) Plebani, M., Bernardi, D., Zaninotto, M. et al.:New and traditional serum markers of bone metabolism in the detection of skeletal metastases. Clin. Biochem. 29:67-72, 1996

24) Elomaa, L, Virkkunen, P., Risteli, L. et al.:Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (I CTP) is a useful prognostic indicator in multiple myeloma. Br. J. Cancer 66:337-341, 1992

25) Abildgaard, N., Bentzen, S.M., Neilsen, J.L. et al.:Serum markers of bone metabolism in multiple myeloma:prognostic value of the carboxy-terminal telopeptide of type I collagen (I CTP). Br. J. Haematol 96:103-110, 1997

26) Carlson, K., Larsson, A., Simonsson, B. et al.:Evaluation of bone disease in multiple myeloma:a comparison between the resorption markers urinary deoxypyridinoline/creatinine (DPD) and serum I CTP, and an evaluation of the DPD/osteocalcin and I CTP/osteocalcin ratio. Eur. J. Haematol. 62:300-306, 1999

27) Peest, D., Deicher, H., Fett, W. et al.:Pyridinium cross-links in multiple myeloma:correlation with clinical parameters and use for monitoring of intravenous clodronate therapy-a pilot study of the German myeloma treatment gourp (GMTG). Eur. J. Cancer 32 (Suppl.):A 2053-A 2057, 1996

28) Clair E.W., Moak, S.A., Wilkinson, W.E. et al:Across sectional analysis of 5 different markers of collagen degradation in rheumatoid arthritis. J. Rheumatol. 25:1472-1479, 1998

29) Kotaniemi, A., Isomaki, H., Hakala, M. et al.:Increased type I collagen degradation in early rheumatoid arthritis. J. Rheumatol. 21:1593-1596, 1994

30) Aman, S., Risteli, J., Luukkainen, R. et al.:The value of synovial fluid analyses in the assessment of knee joint destruction in arthritis in a three year follow up study. Ann. Rheum. Dis. 58:559-562, 1999

31) Miyakawa, M., Tsushima, T., Demura, H.:Carboxy-terminal propeptide of type I collagen (PICP) and carboxy-terminal telopeptide of type I collagen (ICTP) as sensitive markers of bone metabolism in thyroid disease. Endocr. J. 43:701-708, 1996

32) Moller, S., Hansen, M., Hllingso, J. et al:Elevated carboxy terminal cross linked telopeptide of type I collagen in alcoholic cirrhosis:relation to liver and kidney function and bone metabolism. Gut 44:417-427, 1998

33) Guanabens, N., Pares, A., Alvarez, L. et al.:Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis. J. Bone Miner. Res. 13:731-738, 1998

follow-up of bone metastasis from lung cancer. Br. J. Cancer 76:760-764, 1997

P.203 掲載の参考文献

1) Pettifor, J.M., Benson, R.:Congenital malformations associated with the administration of oral anticoagulants during pregnancy. J. Pediatr. 86:459-462, 1975

2) Ducy, P., Desbois, C., Boyce, B. et al.:Increased bone formation in osteocalcin-deficient mice. Nature 382:448-452, 1996

3) Luo, G., Ducy, P., McKee, M.D. et al.:Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. Nature 386:78-81, 1997

4) Plantalech, L., Guillaumont, M., Leclercq, M. et al.:Impaired carboxylation of serum osteocalcin in elderly women. J. Bone Miner. Res. 6:1211-1216, 1991

5) Vergnaud, P., Garnero, P., Munier, P.J. et al.:Undercarboxylated osteocalcin measured with a specific immunoassay predicts hip fracture in elderly women:the EPIDOS study. J. Clin. Endocrinol. Metab. 82:719-724, 1997

6) Shiraki, M., Shiraki, Y., Aoki, C. et al.:Vitamin k 2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J. Bone Miner. Res. 15:515-521, 2000

7) Binkley, N.C., Krueger, D.C., Engelke, J.A. et al.:Vitamin K supplementation reduces serum concentrations of under-gamma-carboxylated osteocalcin in healthy young and elderly adults. Am. J. Clin. Nutr. 72:1523-1528, 2000

8) Haffa, A., Krueger, D., Bruner, J. et al.:Diet-or warfarin-induced vitamin K insufficiency elevates circulating undercarboxylated osteocalcin without altering skeletal status in growing female rats. J. Bone Miner Res. 15:872-878, 2000

9) Liu, G., Peacock, M.:Age-related changes in serum undercarboxylated osteocalcin and its relationships with bone density, bone quality, and hip fracture. Calcif. Tissue Int. 62:286-289, 1998

10) Lamon-Fava, S., Sadowski, J.A., Davidson, K.W. et al.:Plasma lipoproteins as carriers of phyllo-quinone (vitamin K 1) in humans. Am. J. Clin. Nutr. 67:1226-1231, 1998

11) Szulc, P., Chapuy, M.C., Munier, P.J. et al.:Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J. Clin. Invest. 91:1769-1774, 1993

12) Szulc, P., Chapuy, M.C., Meunier, P.J. et al.:Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture:a three year followup study. Bone 18:487-488, 1996

13) Luukinen, H., Kakonen, S.M., Pettersson, K. et al.:Strong prediction of fractures among older adults by the ratio of carboxylated to total serum osteocalcin. J. Bone Miner. Res. 15:2473-2478, 2000

14) Feskanich, D., Weber, P., Willett, W.C. et al.:Vitamin K intake and hip fractures in women:a prospective study. Am J. Clin. Nutr. 69:74-79, 1999

15) Caraballo, P.J., Heit, J.A., Atkinson, E.L. et al.:Long-term use of oral anticoagulants and the risk of fracture. Arch. Intern. Med. 159:1750-1756, 1999

16) Sugiyama, T., Kawai, S.:Carboxylation of osteocalcin may be related to bone quality:apossible mechanism of bone fracture prevention by vitamin K. J. Bone Miner.-Metab. 19:146-149, 2000

第IV 骨粗鬆症と骨代謝マーカー

P.214 掲載の参考文献

1) Miller, P.D., Baran, D.T., Bilezikian, J.P. et al.:Practical clinical application of biochemical markers of bone turnover:consensus of an expert panel. J. Clin. Densitom. 2:323-342, 1999

2) Delmas, P.D., Eastell, R., Garnero, P. et al.:The use of biochemical markers of bone turnover in osteoporosis. Osteoporos. Int. 11 (Suppl.6):S2-S 17, 2000

3) 骨粗鬆症診療における骨代謝マーカーの適正使用に関する指針検討委員会:骨粗鬆症診療における骨代謝マーカーの適正使用ガイドライン (2002年度版). Osteoporos. Jpn. 10:251-261, 2002

4) 中塚喜義, 河面健, 正木秀樹ほか:生化学的骨代謝マーカー測定値の施設問差・変動 (第1報). ホルモンと臨床 50:419-424, 2002

P.218 掲載の参考文献

1) WHO:Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis. WHO Technical Report. 1994, p.843

2) 折茂肇:わが国における骨粗鬆症の新しい診断基準(女性). The Bone 15:251-254, 2001

3) Yasumizu, T., Okuno, T., Fukuda, Y. et al:Age-related changes in b (me mineral density and srum bone-related proteins in premenopausal and postmenopausal Japanese women. Endocr. J. 47:103-109, 2000

4) Taguchi, Y., Gorai, L, Zhang, G. et al:Differences in bone resorption after menopause in Japanese women with normal or low bone mineral density:quantitation of urinary cross-linked N-telope ptides. Calcif. Tissue Int. 62:395-399, 1998

5) Garnero, P., Sornay-Rendu, E., Chapuy, M-C. et al.:Increased bone turnover in late post-menopausal women is a major determinant of osteoporosis. J. Bone Miner. Res. 11:337-349, 1996

6) Marcus, R., Holloway, L., Wells, B. et al.:The relationship of biochemical markers of bone turnover to bone density changes in post menopausal women:results from the postmenopausal estrogen/progestin interventions (PEPI) trial. J. Bone Miner. Res. 14:1583-1595, 1999

P.227 掲載の参考文献

1) Christiansen, C., Riis, B.J., Rodbro, P.:Prediction of rapid bone loss in postmenopausal women. Lancet 1:1105-1108, 1987

2) Christiansen, C., Riis, B.J., Rodbro, P.:Screening procedure for women at risk of developing postmenopausal osteoporosis. Osteoporos. Int. 1:35-40, 1990

3) Slemenda, C., Hui, S.L., Longcopy, C. et al.:Sex steroids and bone mass:astudy of change about the time of menopause. J. Clin. Invest. 80:1261-1269, 1987

4) Johansen, J.S., Riis, B.J., Delmas, P.D. et al.:Plasma BGP:an indicator of spontaneous bone loss and of the effect of oestrogen treatment in postmenopausal women. Eur. J. Clin. Invest. 18:191-195, 1988

5) Rosso, R., Minisola, S., Scarda, A. et al.:Temporal relationship between bone loss and increased bone turnover:alongitudinal study following natural menopause. J. Endocrinol. Invest. 18:723-728, 1995

6) Slemenda, C., Longcope, C, Peacock, M. et al.:Sex steroids, bone mass and bone loss:a prospective study of pre-, peri-and postmenopausal women. J. Clin. Invest. 97:14-21, 1996

7) Garnero, P., Sornay-rendu, E., Duboeuf, F. et al.:Markers of bone turnover predict postmenopausal forearm bone loss over 4 years:the OFELY study. J. Bone Miner. Res. 14:1614-1621, 1999

8) Uebelhart, D., Schlemmer, A., Johansen, J.S. et al.:Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium cross-links. J. Clin. Endocrinol. Metab. 72:367-373, 1991

9) Hesley, R.P., Shepard, K.A., Jenkins, D.K. et al.:Monitoring estrogen replacement therapy and identifying rapid bone losers with an immunoassay for deoxypyridinoline. Osteoporos. Int. 8:159-164, 1998

10) Schlemmer, A., Hassager, C., Delmas, P.D. et al.:Urinary excretion of pyridinium cross-links in healthy women:the long-term effects of menopause and oestrogen/progesterone therapy. Clin. Endocrinol. Exf. 40:777-782, 1994

11) Mole, P.A., Walkinshaw, M.H., Robins, S.P. et al.:Can urinary pyridinium crosslinks and urinary oestrogens predict bone mass and rate of bone loss after the menopause?Eur. J. Clin. Invest. 22:767-771, 1992

12) Rogers, A., Hannon, R.A., Eastell, R.:Biochemical markers as predictors of rates of bone loss after menopause. J. Bone Miner. Res. 15:1398-1404, 2000

13) Iki, M., Kajita, E., Dohi, Y. et al.:Age, menopause, bone turnover markers and lumbar bone loss in healthy Japanese women. Maturitas 25:59-67, 1996

14) Chaki, O., Yoshikata, I., Kikuchi, R. et al.:The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women. J. Bone Miner. Res. 15:1537-1544, 2000

15) Cosman, F., Nieves, J., Wilkinson, C. et al.:Bone density change and biochemical indices of skeletal turnover. Calcif. Tissue Int. 58:236-243, 1996

16) Keen, R.W., Nguyen, T., Sobnack, R. et al.:Can biochemical markers predict bone loss at the hip and spine? A4-year prospective study of 141 early postmenopausal women. Osteopros. Int. 6:399-406, 1996

17) Storm, D., Eslin, R., Porter, E.S. et al.:Calcium supplementation prevents seasonal bone loss and changes in biochemical markers of bone turnover in elderly New England women:arandomized placebo-controlled trial. J. Clin. Endocrinol. Metab. 83:3817-3825, 1998

18) Marcus, R., Holloway, L, Wells, B. et al:The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women:results from the postmenopausal estrogen/progestin interventions (PEPI) trial. J. Bone Miner. Res. 14:1583-1595, 1999

19) Yoshimura, N., Hashimoto, T., Sakata, K. et al.:Biochemical markers of bone turnover and bone loss at the lumbar spine and femoral neck:the Taiji study. Calcif. Tissue Int. 65:198-202, 1999

20) Dennison, E., Eastel, R., Fall, CHD. et al.:Determinants of bone loss in elderly men and women:a prostective population-based study. Osteoporos. Int. 10:384-391, 1999

21) Bauer, D., Sklarin, P.M., Stone, K.L. et al.:Biochenical markers of bone turnover and prediction of hip bone loss in older women:the study of osteoporotic fractures. J. Bone Miner Res. 14:1404-1410, 1999

22) Melton, L.J. III, Atkinson, E.J., O'Connor, M.K. et al.:Determinants of bone loss from the femoral neck in women of different ages. J. Bone Miner. Res. 15:24-31, 2000

23) Dresner-Pollak, R., Parker, R.A., Poku, M. et al:Biochemical markers of bone turnover reflect femoral bone loss in elderly women. Calcif. Tissue Int. 59:328-333, 1996

24) 伊木雅之, 秋葉隆, 西野治身ほか:健常日本人女性における骨代謝マーカーによる骨密度変化の測:JPOS Cohort Study. Osteoporos. Jpn. 10:126-129, 2002

25) Hansen, M.A., Overgaard, K., Riis, B.J. et al.:Role of peak bone mass and bone loss in post-menopausal osteoporosis:12 year study. B.M.J. 303:961-964, 1991

26) Riis, B.J., Hansen, M.A., Jensen, A.M. et al:Low bone mass and fast rate of bone loss at menopause:equal risk factors for future fracture:a 15-year follow-up study. Bone 19:9-12, 1996

27) Kanis, J.A., Melton, L.J., Christiansen, C. et al.:The diagnosis of osteoporosis. J. Bone Miner. Res. 9:1137-1141, 1994

28) Orimo, H., Hayashi, Y., Fukunaga, M. et al.:Diagnostic criteria for primary osteoporosis;year 2000 revision. J. Bone Miner. Metab. 19:331-337, 2001

P.235 掲載の参考文献

1) Garnero, P., Sornay-Rendu, E., Chapuy, M.C. et al.:Increased bone turnover in late post-menopausal women is a major determinant of osteoporosis. J. Bone Miner. Res. 11:337-349, 1996

2) Ross, P.D., Knowlton, W.:Rapid bone loss is associated with increased levels of biochemical markers. J. Bone Miner. Res. 13:297-302, 1998

3) Bauer, D.C, Sklarin, P.M., Stone, K.L. et al.:Biochemical markers of bone turnover and prediction of hip bone loss in older women:the study of osteoporotic fractures. J. Bone Miner. Res. 14:1404-1410, 1999

4) Garnero, P., Hausherr, E., Chapuy, M.C. et al:Markers of bone resorption predict hip fracture in elderly women:the EPIDOS prospective study. J. Bone Miner. Res. 11:1531-1538, 1996

5) Akesson, K., Ljunghall, S., Jonsson, B. et al.:Assessment of biochemical markers of bone metabolism in relation to the occurrence of fracture:a retrospective and prospective population-based study of women. J. Bone Miner. Res. 10:1823-1829, 1995

6) Garnero, P., Sornay-Rendu, E., Claustrat, B. et al.:Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women:the OFELY study. J. Bone Miner. Res. 15:1526-1536, 2000

7) Chapurlat, R.D., Garnero, P., Breart, G. et al.:Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women:the EPIDOS study. Bone 27:283-286, 2000

8) Ross, P.D., Kress, B.C., Parson, R.E. et al.:Serum bone alkaline phosphatase and calcaneus bone density predict fractures:aprospective study. Osteoporos. Int. 11:76-82, 2000

P.245 掲載の参考文献

1) Yoshida, Y., Moriya, A., Kitamura, K. et al.:Responses of trabecular and cortical bone turnover and bone mass and strength to bisphosphonate YH 529 in ovariohysterectomized beagles with calcium restriction. J. Bone Miner. Res. 13:1011-1022, 1998

2) Motoie, H., Nakamura, T., O'uchi, N. et al.:Effects of bisphosphonate YM 175 on bone mineral density, strength, structure, and turnover in ovariectomized beagles on concomitant dietary calcium restriction. J. Bone Miner. Res. 10:910-920, 1995

3) Boivin, G.Y., Chavassieux, P.M., Santora, A.C. et al.:Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 20:485-490, 2000

4) Roxchger, P., Rinnerthaler, S., Yates, J. et al.:Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29:185-1991, 2001

5) Liberman, U.A., Weiss, S.R., Broll, J. et al.:Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N. Engl. J. Med. 333:1437-1443, 1995

6) Black, D.M., Cummings, S.R., Karpf, D.B. et al.:Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541, 1996

7) Cummings, S.R., Black, D.M., Thompson, D.E. et al.:Effect of alendronate on risk of fracture in women with low bone density without vertebral fractures. Results from the Fracture Intervention Trial. JAMA 280:2077-2082, 1998

8) Pols, H.A., Felsenberg, D., Hanley, D.A. et al.:Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass:results of the FOSIT study. Osteoporos. Int. 9:461-468, 1999

9) Shiraki, M., Kushida, K., Fukunaga, M. et al.:A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. Osteoporos. Int. 9:183-192, 1999

10) Tonino, R.P., Meunier, P.J., Emkey, R. et al.:Skeletal benefits of alendronate:7-year treatment of postmenopausal osteoporotic women. J. Clin. Endocrinol. Metab. 85:3109-3115, 2000

11) Black, D.M., Thompson, D.E., Bauer, D.C. et al.:Fracture risk reduction with alendronate in women with osteoporosis:the Fracture Intervention Trial. J. Clin. Endocrinol. Metab. 85:4118-4124, 2000

12) Orwoll, E., Ettinger, M., Weiss, S. et al.:Alendronate for the treatment of osteoporosis in men. N. Engl. J. Med. 343:604-610, 2000

13) Saag, K.G., Emkey, R., Schintzer, T.J. et al.:Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N. Engl. J. Med. 339:292-299, 1998

14) Adachi, J.D., Saag, K.G., Delmas, P. et al.:Two-year effect of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids. Arthritis Rheum. 44:202-211, 2001

15) Cardna, J.M., Pastor, E.:Calcitonin versus etidronate for the treatment of postmenopausal osteoporosis:a meta-analysis of published clinical trials. Osteoporos. Int. 7:165-174, 1997

16) Braga de Castro Machado, A., Hannon, R., Eastell, R.:Monitoring alendronate therapy for osteoporosis. J. Bone Miner. Res. 14:602-608, 1999

17) Greenspan, S., Parker, R.A., Ferguson, L. et al.:Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women:a randomized trial. J. Bone Miner. Res. 13:1431-1438, 1998

18) Bettica, P., Bevilacqua, M., Vago, T. et al.:Short-term variations in bone remodeling biochemical markers:cyclical etidronate and alendronate effects comapared. J. Clin. Endocrinol. Metab. 82:3034-3039, 1997

19) 三木隆巳, 中弘志:エチドロネート治療における骨代謝マーカー. Osteoporos. Jpn. 9:297-302, 2001

P.259 掲載の参考文献

1) 杉本修:生殖・内分泌委員会報告. 本邦婦人における退行期骨粗鬆症予防のための管理方式. 日産婦学会誌 45:603-614, 1993

2) Taguchi, Y., Gorai, I., Chaki, O. et al.:Differences in bone resorption after menopause in Japanese women with normal or low bone mineral density:quantitation of urinary cross-linked N-telopeptides. Calcif. Tissue Int. 62:359-369, 1998

3) 五来逸雄:加齢による骨代謝の変化とエストロゲンの生理学的意義に関する研究. 日産婦学会誌 49:537-545, 1997

4) 細井孝之:骨代謝マーカーの生物学的変動と有意変化. Osteoporos. Jpn. 9:283-287, 2001

5) Marcus, R., Holloway, L., Wells, B. et al.:The relationship of biochemical markers of bone turnover to bone density changes in postmenopausal women:results from the Postmenopausal Estrogen/Progestin Interventions(PEPI) Trial. J. Bone Miner. Res. 14:1583-1595, 1999

6) Rosen, C.J., Chesnut III, C.H., Mallinah, N.J.S. et al.:The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J. Clin. Endocrinol. Metab. 82:1904-1910, 1997

7) Johansen, J.S., Riis, B.J., Delmas, P.D. et al.:An indicator of spontaneous bone loss and the effect of estrogen treatment in postmenopausal women. Eur. J. Clin. Invest. 18:191-195, 1988

8) Cooper, C., Stakkesdad, J.A., Radowicki, S. et al.:Matrix delivery transdermal 17 β-estradiol for the prevention of bone loss in postmenopausal women. Osteoporos. Int. 9:358-366, 1996

9) Chesnut III, C.H., Bell, N.H., Clark, G.S. et al.:Hormone replacement therapy in postmenopausal women:urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am. J. Med. 102:29-37, 1997

10) Delmas, P.D., Hardy, P., Garnero, P. et al.:Monitoring individual response to hormone replacement therapy with bone markers. Bone 26:553-560, 2000

11) Bjarnason, N.H., Sarkar, S., Duong, T. et al.:Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in post-menopausal osteoporosis. Osteoporos. Int. 12:922-930, 2001

P.267 掲載の参考文献

1) Heshmati, H.M., Khosla, S., Burritt, M.F. et al.:A defect in renal calcium conservation may contribute to the pathogenesis of postmenopausal osteoporosis. J. Clin. Endocrinol. Metab. 83:1916-1920, 1998

2) Slovick, D.M., Adams, J.S., Neer, R.M. et al.:Deficient production of 1,25-dihydroxyvitamin D in elderly osteoporotic patients. N. Engl. J. Med. 305:372-374, 1981

3) Ebeling, P.R., Sandgren, M.E., DiMagno, E.P. et al.:Evidence of an age-related decrease in intestinal responsiveness to vitamin D:relationship between serum 1,25-dihydroxyvitamin D3 and intestinal vitamin D receptor concentrations in normal women. J. Clin. Endocrinol. Metab. 75:176-182, 1992

4) Shiraishi, A., Takeda, S., Masaki, T. et al.:Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis:distinct action from estrogen. J. Bone Miner. Res. 15:770-779, 2000

5) Shiraki, M., Kushida, K., Fukunaga, M. et al.:A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. Osteoporos. Int. 10:183-192, 1999

6) Chen, J.T., Shiraki. M., Hasumi, K. et al.:1 α-hydroxyvitamin D3 treatment decreases bone turnover and modulates calcium-regulating hormones in early postmenopausal women. Bone 20:557-562, 1997

7) Zhan, Z., Yamamoto, I., Morita, R. et al.:Urinary pyridinoline and deoxypyridinoline as bone metabolic markers in predicting therapeutic effects of estrogen and alfacalcidol in women with osteoporosis. J. Bone Miner. Res. 17:113-118, 1999

8) Orimo, H., Shiraki, M., Hayashi, Y. et al.:Effects of 1α-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis. Calcif. Tissue Int. 54:370-376, 1994

9) Shiraki, M.:A prospective three-year clinical open-label 1α(OH)D3 trial on fracture rate. Satellite symposium of World Congress on Osteoporosis, 2000

10) 橋本淳, 富田哲也, 越智隆弘ほか:ビタミンDとK併用, ビタミンDとエチドロネート併用投与後の骨代謝マーカーの変動-慢性関節リウマチ患者での検討. Osteoporos. Jpn. 8:107-110, 2000

11) Shiraki, M., Shiraki, Y., Aoki, C. et al.:Vitamin K2(menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J. Bone Miner. Res. 15:515-521, 2000

12) 小林千益, 白木正孝, 高岡邦夫ほか:ビスフォスフォネートと活性型ビタミンDの併用について. 骨粗鬆症の薬剤併用療法に関する多施設共同研究 (中間報告):第1回骨粗鬆症学会, 1999

13) 白木正孝:ビタミンKとビタミンDの骨折予防効果について:第1回骨粗鬆症学会, 1999

14) Sugiyama, T., Tanaka, H., Kawai, S.:Clinical vignette:vitamine K plus vitamin D treatment of bone problems in a child with skeletal unloading. J. Bone Miner. Res. 14:1466-1467, 1999

P.273 掲載の参考文献

1) 折茂肇ほか:骨粗鬆症に対するEa-0167(Menatetrenone)の臨床評価-アルファカルシドールを対照とした臨床第III相多施設二重盲検比較試験. 臨床評価 20:45-100, 1992

2) Shiraki, M., Shiraki, Y., Aoki, C. et al.:Vitamin K2(menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. J. Bone Miner. Res. 15:515-521, 2000

3) Plantalech, L, Guillaumont, M., Vergnaud, P. et al.:Impairment of gamma carboxylation of circulating osteocalcin (bone gla protein) in elderly women. J. Bone Miner. Res. 6:1211-1216, 1991

4) Szulc, P., Chapuy, M.C., Meunier, P.J. et al:Serum undercarboxylated osteocalcin is a marker of the risk of hip fracture in elderly women. J. Clin. Invest. 91:1769-1774, 1993

5) Kaneki, M., Hedges, S.J., Hosoi, T. et al:Japanese fermented soybean food as the major determinant of the large geographic difference in circulating levels of vitamin K2:possible implications for hip-fracture risk. Nutrition 17:315-321, 2001

6) Hara, K., Akiyama, Y., Nakamura, T. et al.:The inhibitory effect of vitamin K2(menatetrenone) on bone resorption may be related to its side chain. Bone 16:179-184, 1995

P.282 掲載の参考文献

1) van Staa, T.P., Leufkens, H.G., Abenhaim, L. et al.:Use of oral corticosteroids and risk of fractures. J. Bone Miner. Res. 15:993-1000, 2000

2) American College of Rheumatology Task Force on Osteoporosis Guidelines:Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum. 39:1791-1801, 1996

3) Eastell, R., Reid, D.M., Compston, J. et al.:A UK Consensus Group on management of glucocorticoid-induced osteoporosis:an update. J. Intern. Med. 244:271-292, 1998

4) Manolagas, S.C., Weinstein, R.S.:New developments in the pathogenesis and treatment of steroid-induced osteoporosis. J. Bone Miner. Res. 14:1061-1066, 1999

5) Kumar, R.:Glucocorticoid-induced osteoporosis. Curr. Opin. Nephrol. Hypertens. 10:589-595, 2001

6) Glucocorticoid-induced osteoporosis:summary of a workshop. J. Clin. Endocrinol. Metab. 86:5681-5685, 2001

7) Canalis, E.:Clinical review 83:mechanisms of glucocorticoid action in bone:implications to glucocorticoid-induced osteoporosis. J. Clin. Endocrinol. Metab. 81:3441-3447, 1996

8) 名和田新:ステロイド性骨粗鬆症. 日本内科学会雑誌 89:2116-2121, 2000

9) Weinstein, R.S., Jilka, R.L, Parfitt, A.M. et al.:Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J. Clin. Invest. 102:274-282, 1998

10) Suda, T., Takahashi, N., Udagawa, N. et al.:Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr. Rev. 20:345-357, 1999

11) Lane, N.E., Sanchez, S., Modin, G.W. et al.:Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis:results of a randomized controlled clinical trial. J. Bone Miner. Res. 15:944-951, 2000

12) 岡本純明, 桐山健:糖質ステロイド骨粗鬆症. 骨代謝マーカー. (西沢良記編) 医薬ジャーナル社, 2001, p.192-200

13) Chiodini, I., Carnevale, V., Torlontano, M. et al.:Alterations of bone turnover and bone mass at different skeletal sites due to pure glucocorticoid excess:study in eumenorrheic patients with Cushing's syndrome. J. Clin. Endocrinol. Metab. 83:1863-1867, 1998

14) Godschalk, M.F., Downs, R.W.:Effect of short-term glucocorticoids on serum osteocalcin in healthy young men. J. Bone Miner. Res. 3:113-115, 1988

15) Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis:2001 update. American College of Rheumatology Ad Hoc Committee on Glucocoritcoid-Induced Osteoporosis. Arthritis Rheum. 44:1496-1503, 2001

16) 日本骨粗鬆症学会骨粗鬆症診療における骨代謝マーカーの適正使用に関する指針検討委員会:骨粗鬆症診療における骨代謝マーカーの適正使用ガイドライン(2001年度版). Osteoporos. Jpn. 9:255-264, 2001

17) Adachi, J.D., Saag, K.G., Delmas, P.D. et al.:Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids:arandomized, double-blind, placebo-controlled extension trial. Arthritis Rheum. 44:202-211, 2001

18) Lane, N.E., Sanchez, S., Genant, H.K. et al.:Short-term increases in bone turnover markers predict parathyroid hormone-induced spinal bone mineral density gains in postmenopausal women with glucocorticoid-induced osteoporosis. Osteoporos. Int. 11:434-442, 2000

P.298 掲載の参考文献

1) 太田博明:骨代謝マーカーの運用に向けて. 臨床と薬物治療 19:963-968, 2000

2) Faulkner, K.G.:Bone matters:are density increases necessary to reduce fracture risk? J. Bone Miner. Res. 15:183-187, 2000

3) Eyre, D.R.:Biochemical basis of collagen metabolites as bone turnover markers. Principles of Bone Biology 11. Academic Press, 1996, p.143-153

4) Robins, S.P., Woitge, H., Hesley, R. et al.:Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J. Bone Miner. Res. 9:1643-1649, 1994

5) 牧田和也, 太田博明:骨代謝マーカー. 検査と技術 29:1469-1472, 2001

6) Delmas, P.D., Eastell, R., Garnero, P. et al.:The use of biochemical markers of bone turnover in osteoporosis. Osteoporos. Int. 11 (Suppl 6):S2-S17, 2000

7) 折茂肇, 山本逸雄, 太田博明ほか:骨粗鬆症治療(薬物療法) に関するガイドライン. Osteoporos. Jpn. 6:203-253, 1998

8) Civitelli, R., Gonnelli, S., Zacchei, F. et al.:Bone turn over in postmenopausal osteoporosis, effect of calcitonin treatment. J. Clin. Invest. 82:1268-1274, 1988

9) Nielsen, N.M., von der Recke, P., Hansen, M.A. et al:Estimation of the effect of salmon calcitonin in established osteoporosis by biochemical bone markers. Calcif. Tissue Int. 55:8-11, 1994

10) Garnero, P., Delmas, P.D.:New developments in biochemical markers for osteoporosis. Calcif. Tissue Int. 59 (Suppl. 1):S2-S9, 1996

11) Silverman, S.L, Greenwald, M., Klein, R.A. et al:Effect of bone density information on decisions about hormone replacement therapy:arandmized trial. Obstet. Gynecol. 89:321-325, 1997

12) Melton, L.J. III., Khosla, S., Atkinson, E.J. et al.:Relationship of bone turnover to bone density and fractures. J. Bone Miner. Res. 12:1083-1091, 1997

13) Garnero, P., Hausherr, E., Chapuy,M. C. et al.:Markers of bone resorption predict hip fracture in elderly women:the EPIDOS prospective study. J. Bone Miner. Res. 11:1531-1538, 1996

14) Garnero, P., Sornay-Rendu, E., Claustrat, B. et al.:Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women:the OFELY study. J. Bone Miner. Res. 15:1526-1536, 2000

15) Vergnaud, P., Garnero, P. Meunier, P.J. et al.:Undercarboxylated osteocalcin measured with a specific immnoassay predicts hip fracture in elderly women.:the EPIDOS study. J. Clin. Endocrinol. Metab. 82:719-724, 1997

16) Bonde, M., Qvist, P., Fledelius, C. et al.:Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps):follow-up on hormone replacement therapy and osteoporosis risk assessment. J. Clin. Endocrinol. Metab. 80:864-868, 1995

17) Rosen, C.J., Chestnut, C.H. III., Mallinak, N.J.S.:The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J. Clin. Endocrinol. Metab. 82:1904-1910, 1997

18) 水口弘司, 五来逸雄, 佐藤章ほか:閉経後女性の薬物療法前後における新しい骨代謝マーカー, I型コラーゲン架橋N-テロペプチド (NTX) の測定. 産婦人科の世界 49:133-138, 1997

19) van, Daele, P.L.A., Seibel, M.J., Burger, H., et al.:Case-control analysis of bone resorption markers, disability, and hip fracture risk:the Rotterdam study. BMJ 312:482-483, 1996

20) Ross, P.D., Kress, B.C., Parson, R.E. et al.:Serum bone alkaline phosphatase and calcaneus bone density predict fractures:a prospective study. Osteoporos. Int. 11:76-82, 2000

21) Garnero, P., Shis, W.J., Gineyts, E. et al.:Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J. Clin. Endocrinol. Metab. 79:1963-1700, 1994

22) Garnero, P., Gineyts, E., Arbault, P. et al.:Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone crosslinks excretion. J. Bone Miner. Res. 10:641-649, 1995

23) 井上哲郎, 串田一博, 熊澤やすしほか:骨粗鬆症患者に対する薬物治療の効果判定における尿中I型コラーゲン架橋N-テロペプチド (NTX) の有用性の検討. Geriatric Med. 35:1441-1447, 1997

24) Mallinak, N.:Crosslinked N-telopeptides of bone collagen:a marker of bone resorption. J. Clin. Ligand Assay 21:111-117, 1998

25) 太田博明, 牧田和也:ホルモン補充療法. ホルモンと臨床 48:151-160, 2000

26) Calvo, M.S., Eyre, D.R., Gundberg, C.M.:Molecular basis and clinical application of biological markers of bone turnover. Endocr. Rev. 17:333-368, 1996

27) Chesnut, C.H. III., Bell, N.H., Clark, G.S. et al.:Hormone replacement therapy in postmenopausal women:urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density. Am. J. Med. 102:29-37, 1997

28) Johansen, J.S., Riis, B.J., Delmas, P.D. et al.:Plasma BGP:an indicator of spontaneous bone loss and the effect of oestrogen treatment in postmenopausal women. Eur. J. Clin. Invest. 18:191-195, 1988

29) Cooper, C., Stakkesdad, J.A., Radowicki, S. et al.:Matrix delivery transdermal 17 B estradiol for the prevention of bone loss in postmenopausal women. Osteoporos. Int. 9:358-366, 1999

30) Riis, B.J., Overgeerd, K., Christiansen, C.:Biochemical markers of bone turnover to monitor the bone mass response to postmenopausal hormone replacement therapy. Osteoporos. Int. 5:276-280, 1995

31) Rosen, C.J., Chesnut, C.H. III., Mallinak, N.J.:The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J. Clin. Endocrinol. Metab. 82:1904-1910, 1997

32) Delmas, P.D., Bjarnasson, N.H., Mitlak, B.H. et al.:Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N. Engl. J. Med. 337:1641-1647, 1997

第V章骨粗鬆症以外の疾患・状態と骨代謝マーカー

P.310 掲載の参考文献

1) Hiraga, T., Tanaka, S., Ikegami, M. et al.:Morphology of bone metastasis. Eur. J. Cancer 34:230-239, 1998

2) Clarke, N.W., McClure, J., George, N.J.R.:Morphometric evidence for bone resorption and replacement in prostate cancer. Br. J. Urol. 68:74-80, 1991

3) Garnero, P., Shin, W.J., Gineyts, E. et al.:Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J. Clin. Endocrinol. Metab. 79:1693-1700, 1994

4) Koizumi, M., Takahashi, S., Ogata, E.:Bone metabolic marker in bone metastasis of breast cancer. Int. J. Clin. Oncol. 4:331-337, 1999

5) Atley, L.M., Mort, J.S., Lalumiere, M. et al.:Proteolysis of human collagen by cathepsin K:characterization of the cleavage sites generating the cross-linked N-telopeptide neoepitope. Bone 26:241-247, 2000

6) Sassi, M.L., Eriksen, H., Risteli, L. et al.:Immunochemical characterization of assay for carboxyterminal telopeptide of human type I collagen:loss of antigenecity by treatment with cathepsin K. Bone 26:367-373, 2000

7) Halleen, J.M., Alatalo, S.L., Suomillen, H. et al.:Tartrate-resistant acid phosphatase 5 b:a novel serum marker of bone resorption. J. Bone Miner. Res. 15:1337-1345, 2000

8) Stein, G.S., Lian, J.B., Owen, T.A.:Relationship of cell growth to the regulation of tissue-specific gene expression during osteoblast differentiation. FASEB J. 4:3111-3123, 1990

9) Ducy, P., Desbois, C., Boyce, B. et al:Increased bone formation in osteocalcin-deficient mice. Nature 382:448-452, 1996

10) Yamaguchi, T., Tamai, K., Yamamoto, M. et al.:Intertrabecullar pattern of tumor metastatic to bone. Cancer 78:1388-1394, 1996

11) 小泉満:骨シンチグラフィー:骨転移を探る(遠藤啓吾編). メディカルチャー, 東京, 2000, p1-2, p43-47

12) Koizumi, M., Yonese, J., Fukui, I. et al.:Serum PINP level is a sensitive marker of prostate cancer metastasis to bone. BJU Int. 87:348-351, 2001

13) Koizumi, M., Maeda, H., Yoshimura, K. et al.:Dissociation of bone formation markers in bone metastasis of prostate cancer. Br. J. Cancer 75:1601-1604, 1997

14) Maeda, H., Koizumi, M., Yoshimura, K. et al.:Correlation between bone metabolic markers and bone scan in prostatic cancer. J. Urol. 157:539-543, 1997

15) Aruga, A., Koizumi, M., Hotta, R. et al.:Usefulness of bone metabolic markers in the diagnosis and follow up of bone metastasis from lung cancer. Br. J. Cancer 76:760-764, 1997

16) Koizumi, M., Matsumoto, S., Takahashi, S. et al.:Bone metabolic markers are useful in the diagnosis of bone scan flare phenomenon in bone metastases from breast cancers. Clin. Nucl. Med. 24:15-20, 1999

17) Diel, I.J., Solomayer, E.F., Siebel, M.J. et al:Serum sialoprotein in patients with primary breast cancer is prognostic marker for subsequent bone metastasis. Clin. Cancer Res. 5:3914-3919, 1999

18) American Society of Clinical Oncology:Recommended breast cancer surveillance guidelines. J. Clin. Oncol. 15:2149-2156, 1997

19) Koizumi, M., Yonese, J., Fukui, I. et al:Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer. J. Urol. 167:1863-1866, 2002

20) Hortbagyi, G.B., Theriault, R.L., Lipton, A. et al.:Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J. Clin. Oncol. 16:2038-2044, 1998

21) Theriault, R.L, Lipton, A., Hortobagyi, G.N. et al.:Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions:arandomized, placebo controlled trial. J. Clin. Oncol. 17:846-854, 1999

22) Berenson, J.R., Rosen, L.S., Howell, A. et al.:Zoledronic acid reduces skeletal related events in patients with osteolytic metastasis. Cancer 91:1191-1120, 2001

23) Lipton, A., Demers, L, Curley, E. et al.:Markers of bone resorption in patients treated with pamidronate. Eur. J. Cancer 34:2021-2026, 1998

24) 尾浦正二, 桜井武雄, 吉村吾郎ほか:ビスフォスフォネート療法の効果判定. 乳癌の臨床 14:201-207, 1999

25) Koizumi, M., Kobayashi, M., Furukawa, M. et al.:The bisphosphonate incadronate for bone metastases of breast cancer. Int. J. Clin. Oncol. 5:241-246, 2000

26) Takahashi, S., Yoshida, N., Koizumi, M. et al.:Biochemical markers of bone metabolism predicts prognosis in patients with bone metastasis of breast cancer. Breast Cancer Res. Treat. 64:97, 2000

P.321 掲載の参考文献

1) Silverberg, S.J., Gartenberg, F., Jacobs, T.P. et al.:Longitudinal measurements of bone mineral density and biochemical indices in untreated primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 80:723-728, 1995

2) Silverberg, S.J., Shane, E., Jacobs, T.P. et al.:A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery. N. Engl. J. Med. 341:1249-1255, 1999

3) Kobayashi, T., Sugimoto, T., Kobayashi, A. et al.:Vitamin D receptor genotype is associated with cortical bone loss in Japanese patients with primary hyperparathyroidism. Endocr. J. 45:123-125, 1998

4) Kanzawa, M., Sugimoto, T., Kobayashi, T. et al.:Parathyroid hormone gene polymorphisms in primary hyperparathyroidism. Clin. Endocrinol. 50:583-588, 1999

5) Kanzawa, M., Sugimoto, T., Kobayashi, T. et al.:Association of parathyroid hormone (PTH)/PTH-related peptide receptor gene polymorphism with the extent of bone mass reduction in primary hyperparathyroidism. Horm. Metab. Res. 32:355-358, 2000

6) Yamauchi, M., Sugimoto, T., Yamaguchi, T. et al.:Association of polymorphic alleles at the calcium-sensing receptor gene with clinical severity of primary hyperparathyroidism. Clin. Endocrinol. 55:373-379, 2001

7) Carling, T., Rastad, J., Kindmark, A. et al.:Estrogen receptor gene polymorphism in post-menopausal primary hyperparathyroidism. Surgery 122:1101-1106, 1997

8) Arnold, A., Staunton, C.E., Kim, H.G. et al.:Monoclonality and abnormal parathyroid hormone gene in parathyroid adenoma. N. Engl. J. Med. 318:658-662, 1988

9) Cryns, V.L, Thor, A., Xu, H.J. et al.:Loss of the retinoblastoma tumor-supprresor gene in parathyroid carcinoma. N. Engl. J. Med. 330:757-761, 1994

10) Cryns, V.L., Rubio, MP, Thor, A.D. et al.:p 53 abnormalities in human parathyroid carcinoma. J. Clin. Endocrinol. Metab. 78:1320-1324, 1994

11) Larsson, C., Skagseid, B., Oberg, K. et al.:Multiple endocrine neoplasia type I gene maps to chromosome II and is lost in insulinoma. Nature 332:85-87, 1988

12) Mulligan, L.M., Kwok, J.B., Healey, C.S. et al.:Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2 A. Nature 363:458-460, 1993

13) Arnold. A., Kim. H.G.:Clonal loss of one chromosome II in a parathyroid adenoma. J. Clin. Endocrinol. Metab. 69:496-499, 1989

14) Kifro, O., Moore, F.D., Wang, P. et al.:Reduced immunostaining for the extracellular Ca-sensing receptor in primary and uremic secondary hyperparathyroidism. J. Clin. Endocrinol. Metab. 81:1596-1606, 1996

15) Carling, T., Kindmark, A., Hellman, P. et al.:Vitamin D receptor genotypes in primary hyperparathyroidism. Nature Med. 1:1309-1311, 1995

16) Nagasaka, S., Ishikawa, S., Matoba, H. et al:Vitamin D receptors and hyperparathyroidism Nat. Med. 2:834, 1996

17) Khosla, S., Melton, L.J. III., Wermers, R.A. et al.:Primary hyperparathyroidism and the risk of fracture:apopulation-based study. J. Bone Miner. Res. 14:1700-1707, 1999

18) Takami, H., Ikeda, Y., Hayashi, Y. et al.:Clinical assessment of collagen crosslinked N-telopeptides as a marker of bone metabolism in patients with primary hyperparathyroidism. Biomed. Pharmacother. 53:329-333, 1999

19) Nakaoka, D., Sugimoto, T., Kobayashi, T. et al.:Evaluation of changes in bone mineral density and biochemical parameters after parathyroidectomy in primary hyperparathyroidism Endocr. J. 47:231-237, 2000

20) NIH conference:Diagnosis and management of asymptomatic primary hyperparathyroidism:consensus development conference statement. Ann. Intern. Med. 114:593-597, 1991

21) Silverberg, S.J., Gartenberg, F., Jacobs, T.P. et al.:Increased bone mineral density after parathyroidectomy in primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 80:729-734, 1995

22) Nakaoka, D., Sugimoto, T., Kobayashi, T. et al.:Prediction of bone mass changes after parathyroidectomy in patients with primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 85:1901-1907, 2000

23) Kobayashi, T., Sugimoto, T., Chihara, K.:Clinical and biochemical presentation of primary hyperparathyroidism in Kansai district of Japan. Endocr. J. 44:595-601, 1997

24) Sivula, A., Pelkonen, R.:Long-term health risk of primary hyperparathyroidism:the effect of surgery. Ann. Med. 28:95-100, 1996

25) Sosa, J.A., Powe, N.R., Levine, M.A. et al.:Thresholds for surgery and surgical outcomes for patients with primary hyperparathyroidism:anational survey of endocrine surgeons. J. Clin. Endocrinol. Metab. 83:2658-2665, 1998

26) Kaji, H., Sugimoto, T., Kanatani, M. et al.:Estrogen blocks parathyroid hormone (PTH)-stimulated osteoclast-like cell formation by selectively affecting PTH-responsive cAMP pathway. Endocrinology 137:2217-2224, 1996

27) Kanatani, M., Sugimoto, T., Takahashi, Y. et al:Estrogen via the es. trogen receptor blocks cAMP-mediated parathyroid hormone-stimulated osteoclast formation. J. Bone Miner. Res. 13:854-862, 1998

28) Diamond, T., Ng, A.T., Levy, S. et al.:Estrogen replacement may be an alternative to parathyroid surgery for the treatment of osteoporosis in elderly postmenopausal women presenting with primary hyperparathyroidism:apreliminary report. Osteoporos. Int. 6:329-333, 1996

29) Tal, A., Gravens, L:Intravenous pamidronate for hypercalcemia of primary hyperparathyroidism. South Med. J. 89:637-640, 1996

30) Rossini, M., Gatti, D., Isaia, G. et al:Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism. J. Bone Miner. Res. 16:113-119, 2001

31) Silverberg, S.J., Bone, H.G., Marriott, T.B. et al.:Short-term inhibition of parathyroid hormone secretion by a calcium receptor agonist in patients with primary hyperparathyroidism. N. Engl. J. Med. 337:1506-1510, 1997

32) Collins, M.T., Skarulis, M.C., Bilezikian, J.P. et al.:Treatment of hypercalcemia secondary to parathyroid carcinoma with a novel calcimimetic agent. J. Clin. Endocrinol. Metab. 83:1083-1088, 1998

33) Silverberg, S.J., Locker, F.G., Bilezikian, J.P. et al.:Vertebral osteopenia:a new indication for surgery in primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 81:4007-4012, 1996

34) Christiansen, P., Steiniche, T., Brixen, K. et al.:Primary hyperparathyroidism:short-term changes in bone remodeling and bone mineral density following parathyroidectomy. Bone 25:237-244, 1999

35) Hoshino, H., Kushida, K., Takahashi, M. et al.:Short-term effect of parathyroidectomy on biochemical markers in primary and secondary hyperparathyroidism Miner. Electrolyte Metab. 23:93-99, 1997

36) Thorsen, K., Kristoffersson, A.O., Lorentzon, R.P.:Changes in bone mass and serum markers of bone metabolism after parathyroidectomy. Surgery 122:882-887, 1997

P.330 掲載の参考文献

1) Coburn, J. W.:Renal osteodystrophy. Kidney Int. 17:667-693, 1980

2) Sherrard, D.J., Hercz, G., Pei, Y., et al.:The spectrum of bone disease in end-stage renal failure-an evolving disorder. Kidney Int. 43:436-442, 1993

3) Sherrard, D. J., Ott, S. M., Maloney, N. A. et al.:Uremic osteodystrophy;classification, cause and treatment. in Clinical Disorder of Bone and Mineral Metabolism (Pott, J. B. Jr. ed.) Excerpta Medica, Amsterdam, 1983, p. 254-259

4) Andress, D. L, Maloney, L. A., Coburn, J. W. et al.:Osteomalasia and aplastic bone disease in aluminum related osteodystrophy. J. Clin. Endocrinol. Metab. 65:11-16, 1987

5) Charhon, S. A., Chevassieux, P. M., Chapuy, M. C. et al.:Lower rate of bone formation with or without histologic appearance of osteomalasia in patients with aluminum intoxication. J. Lab. Clin. Med. 106:123-131, 1985

6) Moriniere, P., Cohen-Salal, M., Belbrik, S. et al.:Disappearance of aluminic bone disease in a long term asymptomatic dialysis population restricting A1 (OH)3 intake:emergence of an idiopatic adynamic bone disease not related to aluminum. Nephron 53:93-101, 1989

7) Massry, S. G., Coburn, J. W., Lee, D. B. et al.:Skeletal Resistance to parathyroidism hormone in renal failure. Studies in 105 human subjects. Ann Intern. Med. 78:357-364, 1973

8) 田畑勉, 西澤良記:臨床透析 13:121-128, 1997

9) 三浦義昭, 石山剛, 寺邑朋子ほか:血液透析患者のaplastic bone diseaseの診断における血清骨型アルカリフォスファターゼの有用性について. 腎と骨代謝 12:285-295, 1999

10) Urena, P., Hruby, M., Ferreira, A. et al.:Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J. Am. Soc. Nephrol. 7:506-512, 1996

11) Coen, G., Ballanti, P., Bonucci, E. et al.:Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Nephrol. Dial. Transplant 13:2294-2302, 1998

12) Mugnusson, P., Sharp, C.A., Magnusson, M., et al.:Effect of chronic renal failure on bone turnover and bone alkaline phosphatase isoforms. Kidney Int. 60:257-265, 2001

13) Nakatsuka, K., Miki, T., Nishizawa, Y. et al.:Circulating bone Gla ptotein in end-stage renal disease determined by newly developed two-site immunoradiometric assay. Contrib. Nephrol. 90:147-154, 1991

14) 中塚喜義, 関谷喜一郎, 吉田博昭ほか:日本骨代謝学会雑誌 10:173-180, 1992

15) Risteli, J., Elomaa, I., Niemi, S. et al.:Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen:a new serum marker of bone collagen degradation. Clin. Chem. 39:635-640, 1993

16) Eriksen, E. F, Charles, P., Melsen, F. et al.:Serum markers of type I collagen formation and degradation in metabolic bone disease:correlation with bone histomorphometry. J. Bone Miner. Res. 8:127-132, 1993

17) Nakanishi, M., Yoh, K., Uchida, K. et al.:Clinical usefulness of serum tartrate-resistant fluoride-sensitive acid phosphatase activity in evaluating bone turnover. J. Bone Miner. Metab. 17:125-130, 1999

18) 影林頼明, 三馬省二, 米田龍生ほか:腎性骨異栄養症における血清ピリジノリン類の測定とその臨床的意義. Jpn. Nephrol. 37:397-403, 1995

19) Urena, P., Ferreira, A., Kung, V.T. et al.:Serum pyridinoline as a specific marker of collagen breakdown and bone metabolism in hemodialysis patient. J. Bone Miner. Res. 10:932-939, 1995

20) Fletcher, S., Jones R.G., Rayner, H.C. et al.:Assessment of renal osteodystrophy in dialysis patient:use of bone alkaline phosphatase, bone mineral density and parathyroid ultrasound in comparison with bone histology. Nephron 75:412-419, 1997

21) 根木茂雄, 秋澤忠雄:骨のPTHに対する反応性の低下. 腎と透析 48:471-474, 2000

22) 衣笠えり子, 神代志保, 秋澤忠男:骨代謝マーカー. (福永仁夫ほか編) メディカルレビュー社, 1995, p. 240-250

23) 片桐誠, 太多和孝博, 太田喜久子ほか:腎性上皮小体機能亢進症における術前後の血中オステオカルシン濃度の検討. 腎と骨代謝 7:107-114, 1994

P.338 掲載の参考文献

1) Siris, E.S.:Paget's disease of bone. in Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. (Favus, M.J. et al eds.) 2nd ed. Raven Press, New York, 1993, p.83

2) 中塚喜義, 粉河恭子:骨Paget病. 骨カルシウム検査ハンドブック. (森井浩世編) 中山書店, 東京, 1996, p.279-285

3) Sharp, C.A., Worsfold, M., Rowlands, P.R. et al.:Response of biochemical markers of bone turnover to pamidronate infusion in Paget's disease of bone. Semin. Arth. Rheum. 23:242-243, 1994

4) Singer, F.R., Clemens, T.L, Eusebio, R.A. et al.:Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease. J. Clin. Endocrinol. Metab. 83:1906-1910, 1998

5) Khan, S.A., Vasikaran, S., McCloskey, E.V. et al.:Alendronate in the treatment of Paget's disease of bone. Bone 20:263-271, 1997

6) Coulton, L.A., Preston, C.J., Couch, M. et al.:An evaluation of serum osteocalcin in Paget's disease of bone. Arthritis Rheum. 31:1142-1147, 1988

7) Alvarez, L, Guanabens, N., Peris, P. et al:Discrimitive value of biochemical markers of bone turnover in assessing the activity of Paget's disease. J. Bone Miner. Res. 10:458-465, 1995

8) Hamdy, N.A., Papapoulos, S.E., Colwell, A. et al.:Urinary collagen crosslink excretion:abetter index of bone resorption than hydroxyproline in Paget's disease of bone?Bone Miner. 22:1-8, 1993

9) Garnero, P., Gineyts, E., Arbault, P. et al.:Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion. J. Bone Miner Res. 10:641-649, 1995

10) Pedrazzoni, M., Alfano, F.S., Gatti, C. et al.:Acute effects of bisphosphonate on new and traditional markers of bone resorption. Calcif Tissue Int. 57:25-29, 1995

P.348 掲載の参考文献

1) Ross, D.S.:Bone disease in hyperthyroidism. in Bone Disease in Hyperthyroidism. (Avioli, L.V. Krane, S.M. eds.) Academic Press, San Diego, 1998, p.531-544

2) Pantazi, H., Papapetrou, P.D.:Changes in parameters of bone and mineral metabolism during therapy for hyperthyroidism. J. Clin. Endocrinol. Metab. 85:1099-1106, 2000

3) Ross, D.S., Neer, R.M., Rigway, E.C. et al.:Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine. Am. J. Med. 82:1167-1170, 1987

4) Uzzan, B., Campos, J., Cucherat, M. et al.:Effects on bone mass of long term treatment with thyroid hormones:ameta-analysis. J. Clin. Endocrinol. Metab. 81:4278-4289, 1996

5) Cummings, S.R., Nevitt, M.C., Browner, W.S. et al.:Risk factors for hip fracture in white women. N. Engl. J. Med. 332:767-774, 1995

6) Kumeda, Y., Inaba, M., Tahara, H. et al.:Persistent increase in bone turnover in Graves'patients with subclinical hyperthyroidism. J. Clin. Endocrinol. Metab. 85:4157-4161, 2000

7) Franklyn, J.A., Maisonneuve, P., Sheppard, M.C. et al.:Mortality after the treatment of hyperthyroidism with radioactive iodine. N. Engl. J. Med. 338:712-718, 1998

8) Yamamoto, M., Markatos, A., Seedor, J.G.:The effect of the aminobisphosphonate alendronate on thyroid hormone-induced osteopenia in rats. Calcif. Tissue Int. 53:278-282, 1993

9) Lupoli, G., Nuzzo, V., Di Carlo, C. et al:Effects of alendronate on bone loss in pre-and post-menopausal hyperthyroid women treated with methimazole. Gynecol. Endocrinol. 10:343-348, 1996

P.355 掲載の参考文献

1) Deodhar, A.A., Brabyn, J., Jones, P.W. et al.:Longitudinal study of hand bone densitometry in rheumatoid arthritis. Arthritis Rheum. 38:1204-1210, 1995

2) Sambrook, P.N., Ansell, B.M., Foster, S. et al.:Bone turnover in early rheumatoid arthritis.2. Longitudinal bone density studies. Ann. Rheum. Dis. 44:580-584, 1985

3) 井手美香子, 鈴木康夫:慢性関節リウマチと骨粗鬆症. 炎症と免疫 2:557, 1994

4) Shimmizu, S., Shiozawa, S., Shiozawa, K. et al.:Quantitative histologic studies on the pathogenesis of periarticular osteoporosis in rheumatoid arthritis. Arthritis Rheum. 28:25-31, 1985

5) Takayanagi, H., Iizuka, H., Juji, T. et al.:Involvement of receptor activator of nuclear factor KB ligand-osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum. 43:259-269, 2000

6) Kotake, S., Udagawa, N., Takahashi, N. et al.:IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 103:1345-1352, 1999

7) Compston, J.E., Vedi, S., Mellish, R.W. et al.:Reduced bone formation in non-steroid treated patients with rheumatoid arthritis. Ann. Rheum. Dis. 48:483-487, 1989

8) Obayashi, O.:Histomorphometric study of the iliac bone in rheumatoid arthritis. Ryumachi 36:627-636, 1996

9) Gough, A.K., Lilley, J., Eyre, S. et al.:Generalised bone loss in patients with rheumatoid arthritis. Lancet 344:23-27, 1994

10) Reid, D.M., Kennedy, N.S., Smith, M.A. et al.:Bone loss in rheumatoid arthritis and primary generalized osteoarthrosis:effects of corticosteroids, suppressive antirheumatic drugs and calcium supplements. Br. J. Rheumatol. 25:253-259, 1986

11) Cooper, A.M., O'sullivan, M.M., Clements, D. et al.:Long-term follow-up of spinal trabecular bone mineral density in women with non-steroid treated rheumatoid arthritis. Ann. Rheum. Dis. 53:149, 1994

12) Gough, A., Sambrook, P., Devlin, J. et al.:Osteoclastic activation is the principal mechanism leading to secondary osteoporosis in rheumatoid arthritis. J. Rheumatol. 25:1282-1289, 1998

13) Shenstone, B.D., Mahmoud, A., Woodward, R. et al.:Longitudinal bone mineral density changes in early rheumatoid arthritis. Br. J. Rheumatol. 33:541-545, 1994

14) Sambrook, P.N., Cohen, M.L, Eisman, J.A. et al.:Effects of Iow dose corticosteroids on bone mass in rheumatoid arthritis:a longitudinal study. Ann. Rheum. Dis. 48:535-538, 1989

15) Aman, S., Hakala, M., Silvennoinen, J. et al.:Low incidence of osteoporosis in a two year follow-up of early community based patients with rheumatoid arthritis. Scand. J. Rhezamatol. 27:188-193, 1998

16) Verhoeven. A.C., Boers, M.:Limited bone loss due to corticosteroids:asystemic review of prospective studies in rheumatoid arthritis and other diseases. J. Rheumatol. 24:1495-1503, 1997

17) Laan, R.F, Buijs, W.C., Verbeek, A.L. et al.:Bone mineral density in patients with recent onset rheumatoid arthritis:influence of disease activity and functional capacity. Ann. Rheum. Dis. 52:21-26, 1993

18) Oelzner, P., Franke, S., Muller, A. et al.:Relationship between soluble markers of immune activation and bone turnover in post-menopausal women with rheumatoid arthritis. Rheumatology 38:841-847, 1999

19) Gough, A.K., Peel, N.F., Eastell, R. et al:Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis. Ann. Rheum. Dis. 53:14-17, 1994

20) Hakala, M., Risteli, L, Manelius, J. et al:Increased type I collagen degeneration correlates with disease severity in rheumatoid arthritis. Ann. Rheum. Dis. 52:866-869, 1993

21) Hakala, M., Aman, S., Luukkainen, R. et al.:Application of markers of collagen metabolism in serum and synovial fluid for assessment of disease process in patients with rheumatoid arthritis.Ann.Rheum.Dis.54:886-890,1995

22) Molenaar, E.T., Lems, W.F., Dijkmans, B.A. et al.:Levels of markers of bone resorption are moderately increased in patients with inactive rheumatoid arthritis. Rheumatology 39:742-744,2000

23) Franck, H., Ittel, T.H., Tasch,O. et al.:Osteocalcin in patients with rheumatoid arthritis-Effect of anatomical stages, inflammatory activity and therapy. Rheumatol.Int.12:207-211,1992

24) Franck, H., Ittel, T.H.,Tasch,O. et al.:Osteocalcin in patients with rheumatoid arthritis. A one-year follow-up study.J.Rheumatol.21:1256-1259,1994

25) Cortet, B., Flip, R.M., Pigny, P. et al.:Is bone turnover a determinant of bone mass in rheumatoid arthritis? J.Rheumatol.25:2339-2344,1998

26) Suzuki, M., Takahashi, M., Miyamoto, S. et al.:The effects of menopausal status and disease activity on biochemical markers of bone metabolism in female patients with rheumatoid arthritis.Br.J.Rheum. 37:653-658,1998

27) Cortet, B., Guyot, M.H., Solau, E. et al.:Factors influencing bone loss in rheumatoid arthritis:a longitudinal study. Clin. Exp. Rheumatol.18:683-690,2000

28) Nishimura, J., Ikuyama, S.:Glucocorticoid-induced osteoporosis:pathogenesis and management.J.Bone Miner.Metab. 18:350-352,2000

29) Ragab, A.H., Frech, R.S., Vietti, T.J. et al.:Osteoporotic fractures secondary to methotrexate therapy in acute leukemia in remission. Cancer 25:580-585,1970

30) Preston, S.J., Diamond, T., Scott, A. et al.:Methotrexate osteopathy in rheumatic diseases.Ann.Rheum.Dis 52:582-585,1993

31) Buckley, LM., Leib, E.S., Cartularo, K.S. et al.:Effect of low dose methotrexate on bone mineral density of patients with rheumatoid arthritis.J. Rheumatol. 24:1489-1494,1997

32) Miedany, Y.M., Abubakr,I.H., El Baddini, M. et al.:Effect of low dose methotrexate on markers of bone metabolism in patients with rheumatoid arthritis.J. Rheumatol. 25:2083-2087,1998

33) Mostov, K., Werb, Z.:Journey across the osteoclast. Science 276:219-220,1997

34) Fisher, J.E., Rogers, M.J., Halasy, J.M. et aL:Alendronate mechanism of action:geranylgeraniol,an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc. Natl.Acad. Sci.USA 96:133-138,1999

35) Colucci, S., Minielli, V., Zambonin, G. et aL:Alendronate reduces adhesion of human osteoclast-like cells to bone and bone protein-coated surfaces. Calcif. Tissue. Int. 63:230-235,1998

36) Luckman, S.P., Coxon, F.P., Ebetino, F.H. et al.:Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation:evidence from structure-activity relationships in J774 macrophages.J. Bone Miner. Res. 13:1668-1678,1998

37) Sansoni, P., Passeri, G., Fagnoni, F. et al.:Inhibition of antigen-presenting cell function by alendronate in vitro.J. Bone Miner. Res. 10:1719-1725,1995

38) Dunn, C.J., Goa, K.L.:Demonstration of novel anti-arthritic and anti-inflammatory effects of diphosphonates.J. Pharmacol.Exp.Ther. 226:1691-1698,1993

39) Cantatore, F.P., Acquista, C.A., Pipitone, V. et al.:Evaluation of bone turnover and osteoclastic cytokines in early rheumatoid arthritis treated with alendronate.J. Rheumatol. 26:2318-2323,1999

40) Eggelmeijer, F., Papapoulos, S.E., van Paassen, H.C. et al.:Clinicla and biochemical response to single infusion of pamidronate in patients with active rheumatoid arthritis:a double blind placebo controlled study.J. Rheumatol. 21:2016-2020,1994

41) Valleala, H., Laitinen, K., Pylkkanen, L. et al.:Clinical and biochemical response to single infusion of clodronate in active rheumatoid arthritis-a double blind placebo controlled study.Inflamm. Res. 50:598-601,2001

42) Falcini, F.,Trapani, S., Ermini, M. et al.:Intravenous administration of alendronate counteracts the in vivo effects of glucocorticoids on bone remodeling. Calcif. Tissue.Int. 58:166-169,1996

43) Schnitzer, T., Bone, H.G., Crepaldi, G. et al.:Therapeutic equivalence of alendronate 70mg once-weekly and alendronate 10mg daily in the treatment of osteoporosis. Alendronate OnceWeekly Study Group.Aging(Milano) 12:1-12,2000

44) Reid,I.R., Brown, J.P., Burckhardt, P. et al.:Intravenous zoledronic acid in postmenopausal women with low bone mineral density.N. Engl.J. Med.346:653-661,2002

P.368 掲載の参考文献

1) Hosoda, K., Kanzaki, S., Eguchi, H. et al.:Secretion of osteocalcin and its propeptide from human osteoblastic cells:dissociation of the secretory patterns of osteocalcin and its propeptide. J. Bone Miner. Res. 8:553-565, 1993

2) Kanzaki, S., Hosoda, K., Moriwake, T. et al.:Serum propeptide and intact molecular osteocalcin in normal children and children with growth hormone (GH) deficiency:a potential marker of bone growth and response to GH therapy. J. Clin. Endocrinol. Metab. 75:1104-1109, 1992

3) Fujimoto, S., Kubo, T., Tanaka, H. et al.:Urinary pyridinoline and deoxypyridinoline in healthy children and in children with growth hormone deficiency. J. Clin. Endocrinol. Metab. 80:1922-1928, 1995

4) Kubo, T., Tanaka, H., Inoue, M. et al.:Serum levels of carboxyterminal propeptide of type I procollagen and pyridinoline crosslinked telopeptide of type I collagen in normal children and children with growth hormone (GH) deficiency during GH therapy. Bone 17:397-401, 1995

5) Tobiume, H., Kanzaki, S., Hida, S. et al:Serum bone alkaline phosphatase isoenzyme levels in normal children and children with growth hormone (GH) deficiency:apotential marker for bone formation and response to GH therapy. J. Clin. Endocrinol. Metab. 82:2056-2061, 1997

6) Kamel, S., Brazier, M., Rogez, J. C. et al.:Different responses of free and peptide-bound crosslinks to vitamin D and calcium supplementation in elderly women with vitamin D insufficiency. J. Clin. Endocrinol. Metab. 81:3717-3721, 1996

7) Scariano, J. K., Walter, E. A., Glew, R. H. et al.:Serum levels of the pyridinoline crosslinked carboxy-terminal telopeptide of type I collagen (ICTP) and osteocalcin in rechitic children in Nigeria. Clin. Biochem. 28:541-545, 1995

8) Crosbie, O. M., Freaney, R., McKenna, M. J. et al:Bone density, vitamin D status, and disordered bone remodeling in end-stage chronic liver disease. Calcif. Tissue Int. 64:295-300, 1999

9) 絹田恵子, 金澤秀美, 田中弘之ほか:アトピー性皮膚炎に合併したビタミンD欠乏性くる病. 日児誌 102:141-144, 1998

10) Scariano, J. K., Vanderjagt, D. J., Thacher, T. et al.:Calcium supplements increase the serum levels of crosslinked N-telopeptides of bone collagen and parathyroid hormone in rachitic Nigerian children. Clin. Biochem. 31:421-427, 1998

11) Sharp, C. A., Oginni, LM., Worsfold, M. et al.:Elevated collagen turnover in Nigerian children with calcium-deficiency rickets. Calcif. Tissue Int. 61:87-94, 1997

12) Lubec, B., Fang-Kircher, S., Lubec, T. et al.:Evidence for McKusick's hypothesis of deficient collagen cross-linking in patients with homocystinuria. Biochim. Biophys. Acta 1315:159-162, 1996

13) Torrents, D., Mykkanen, J., Pineda, M. et al.:Identification of SLC7A7, encoding y(+)LAT-1, as the lysinuric protein intolerance gene. Nature Genet. 21:293-296, 1999

14) Sillence, D. O., Senn, A., Danks, D. M.:Genetic heterogeneity in osteogenesis imperfecta. J. Med. Genet. 16:101-116, 1979

15) Lund, A. M, Hansen, M., Kollerup, G. et al.:Collagen-derived markers of bone metabolism in osteogenesis imperfecta. Acta Paediatr. 87:1131-1137, 1998

16) Cepollaro, C., Gonnelli, S., Pondrelli, C. et al.:Osteogenesis imperfecta:bone turnover, bone density, and ultrasound parameters. Calcif. Tissue Int. 65:129-132, 1999

17) Bank, R. A., Tekoppele, J. M., Janus, G. J. et al.:Pyridinium cross-links in bone of patients with osteogenesis imperfecta:evidence of a normal intrafibrillar collagen packing. J. Bone Miner. Res. 15:1330-1336, 2000

18) Glorieux, F. H., Bishop, N. J., Plotkin, H. et al.:Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N. Engl. J. Med. 339:947-952, 1998

P.376 掲載の参考文献

1) 大島博:宇宙滞在における骨量減少とカルシウムバランス. DENTAL OUTLOOK 89:846-850, 1997

2) Nicogossian, A. E., Huntoon, C. L., Pool, S. L. et al.:Space Physiology and Medicine. 3rd ed., Lea & Febiger, Philadelphia, 1993

3) LeBlanc, A., Schneider, V., Shackelford, L. et al.:Bone mineral and lean tissue after long duration space flight. J. Bone Miner. Res. 11:S 323, 1996

4) Smith, S. M., Wastney, M. E., Morukov, B. V. et al.:Calcium metabolism before, during, and after a 3-month spaceflight:kinetic and biochemical changes. Am. J. Physiol. 277:R1-R 10, 1999

5) Smith, S. M., Nillen, J. L., LeBlanc, A. et al.:Collagen cross-link excretion during space flight and bed rest. J. Clin. Endocrinol. Metab. 83:3584-3591, 1998

6) Caillot-Augusseau, A., Vico, L, Heer, M. et al.:Space flight is associated with rapid decrease of undercarboxylated osteocalcin and increases of markers of bone resorption without changes in their circadian variation:observations in two cosmonauts. Clin. Chem. 46:1136-1143, 2000

7) Schlemmer, A., Hassager, C., Pedersen, B. et al.:Posture, age, menopause and osteopenia do not influence the circadian variation in the urinary excretion of pyridinium crosslinks. J. Bone Miner. Res. 12:1883-1888, 1994

8) Monk, T., Buysse, D., Billy, B. et al.:Sleep and circadian rhythms in four orbiting astronauts. J. Biol. Rhythms. 13:188-201, 1998

9) 大島博, 関口千春, 水野康ほか:16日間以内の宇宙飛行が骨, 筋肉に与える影響. 日整会誌74:S1555, 2000

10) Inoue, M., Tanaka, H., Moriwake, T. et al:Altered biochemical markers of bone turnover in humans during 120 days of bed rest. Bone 26:281-286, 2000

11) Black, D. M., Cummings, S. R., Karpf, D. B. et al.:Randomized trial of effect of alendronate on risk of fracture in woman with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541, 1996

12) Harris, S. T., Watts, N. B., Genant, H. K. et al.:Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis:arandomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA 282:1344-1352, 1999

13) 大島博, 渡辺友紀子, 骨量減少対策助言委員会ほか:日本人宇宙飛行士の骨量減少・尿路結石対策. Osteoporos. Jpn. 9 (Suppl. 1):69, 2001

書評

書評を投稿する

最近チェックした商品履歴

Loading...